ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. **NAME OF THE MEDICINAL PRODUCT**

   Synjardy 5 mg/850 mg film-coated tablets
   Synjardy 5 mg/1,000 mg film-coated tablets
   Synjardy 12.5 mg/850 mg film-coated tablets
   Synjardy 12.5 mg/1,000 mg film-coated tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

   **Synjardy 5 mg/850 mg film-coated tablets**
   Each tablet contains 5 mg empagliflozin and 850 mg metformin hydrochloride.

   **Synjardy 5 mg/1,000 mg film-coated tablets**
   Each tablet contains 5 mg empagliflozin and 1,000 mg metformin hydrochloride.

   **Synjardy 12.5 mg/850 mg film-coated tablets**
   Each tablet contains 12.5 mg empagliflozin and 850 mg metformin hydrochloride.

   **Synjardy 12.5 mg/1,000 mg film-coated tablets**
   Each tablet contains 12.5 mg empagliflozin and 1,000 mg metformin hydrochloride.

   For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

   Film-coated tablet (tablet).

   **Synjardy 5 mg/850 mg film-coated tablets**
   Yellowish white, oval, biconvex film coated tablets debossed with “S5” and the Boehringer Ingelheim logo on one side and “850” on the other side (tablet length: 19.2 mm, tablet width: 9.4 mm).

   **Synjardy 5 mg/1,000 mg film-coated tablets**
   Brownish yellow, oval, biconvex film coated tablets debossed with “S5” and the Boehringer Ingelheim logo on one side and “1000” on the other side (tablet length: 21.1 mm, tablet width: 9.7 mm).

   **Synjardy 12.5 mg/850 mg film-coated tablets**
   Pinkish white, oval, biconvex film coated tablets debossed with “S12” and the Boehringer Ingelheim logo on one side and “850” on the other side (tablet length: 19.2 mm, tablet width: 9.4 mm).

   **Synjardy 12.5 mg/1,000 mg film-coated tablets**
   Dark brownish purple, oval, biconvex film coated tablets debossed with “S12” and the Boehringer Ingelheim logo on one side and “1000” on the other side (tablet length: 21.1 mm, tablet width: 9.7 mm).
4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control

- in patients inadequately controlled on their maximally tolerated dose of metformin alone
- in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin (see sections 4.5 and 5.1 for available data on different combinations)
- in patients already being treated with the combination of empagliflozin and metformin as separate tablets.

4.2 Posology and method of administration

Posology

The recommended dose is one tablet twice daily. The dosage should be individualised on the basis of the patient’s current regimen, effectiveness, and tolerability using the recommended daily dose of 10 mg or 25 mg of empagliflozin, while not exceeding maximum recommended daily dose of metformin.

For patients inadequately controlled on metformin monotherapy or metformin in combination with other glucose-lowering medicinal products including insulin

In patients not adequately controlled on metformin alone or in combination with other glucose-lowering medicinal products, including insulin, the recommended starting dose of Synjardy should provide empagliflozin 5 mg twice daily (10 mg daily dose) and the dose of metformin similar to the dose already being taken. In patients tolerating a total daily dose of empagliflozin 10 mg and who need tighter glycaemic control, the dose can be increased to a total daily dose of empagliflozin 25 mg.

When Synjardy is used in combination with a sulphonylurea and/or insulin, a lower dose of sulphonylurea and/or insulin may be required to reduce the risk of hypoglycemia (see sections 4.5 and 4.8).

For patients switching from separate tablets of empagliflozin and metformin

Patients switching from separate tablets of empagliflozin (10 mg or 25 mg total daily dose) and metformin to Synjardy should receive the same daily dose of empagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.

For the different doses of metformin, Synjardy is available in strengths of 5 mg empagliflozin plus 850 mg metformin hydrochloride, 5 mg empagliflozin plus 1,000 mg metformin hydrochloride, 12.5 mg empagliflozin plus 850 mg metformin hydrochloride, and 12.5 mg empagliflozin plus 1,000 mg metformin hydrochloride.

Special populations

Renal impairment

No dose adjustment is recommended for patients with mild renal impairment. This medicinal product must not be used in patients with moderate or severe renal impairment (creatinine clearance <60 ml/min) (see sections 4.3 and 4.4).

Hepatic impairment

This medicinal product must not be used in patients with hepatic impairment (see sections 4.3, 4.4 and 5.2).

Elderly

Due to the mechanism of action, decreased renal function will result in reduced efficacy of empagliflozin. Because metformin is excreted by the kidney and elderly patients are more likely to
have decreased renal function, Synjardy should be used with caution in these patients. Monitoring of renal function is necessary to aid in prevention of metformin-associated lactic acidosis, particularly in elderly patients (see sections 4.3 and 4.4). In patients 75 years and older, an increased risk for volume depletion should be taken into account (see sections 4.4 and 4.8). Due to the limited therapeutic experience with empagliflozin in patients aged 85 years and older, initiation of therapy in this population is not recommended (see section 4.4).

**Paediatric population**
The safety and efficacy of Synjardy in children and adolescents aged 0 to 18 years has not been established. No data are available.

**Method of administration**
Synjardy should be taken twice daily with meals to reduce the gastrointestinal adverse reactions associated with metformin. All patients should continue their diet with an adequate distribution of carbohydrate intake during the day. Overweight patients should continue their energy restricted diet. If a dose is missed, it should be taken as soon as the patient remembers. However, a double dose should not be taken on the same time. In that case, the missed dose should be skipped.

### 4.3 Contraindications
- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
- Diabetic ketoacidosis, diabetic pre-coma.
- Renal failure or renal dysfunction (creatinine clearance <60 ml/min).
- Acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock.
- Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: decompensated heart failure, respiratory failure, recent myocardial infarction, shock.
- Hepatic impairment, acute alcohol intoxication, alcoholism (see section 4.5).

### 4.4 Special warnings and precautions for use

**General**
Synjardy should not be used in patients with type 1 diabetes.

**Diabetic ketoacidosis**
Rare cases of diabetic ketoacidosis (DKA), including life-threatening cases, have been reported in clinical trials and post marketing in patients treated with SGLT2 inhibitors, including empagliflozin. In a number of cases, the presentation of the condition was atypical with only moderately increased blood glucose values, below 14 mmol/l (250 mg/dl). It is not known if DKA is more likely to occur with higher doses of empagliflozin.

The risk of diabetic ketoacidosis must be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness. Patients should be assessed for ketoacidosis immediately if these symptoms occur, regardless of blood glucose level.

In patients where DKA is suspected or diagnosed, treatment with empagliflozin should be discontinued immediately.

Treatment should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses. In both cases, treatment with empagliflozin may be restarted once the patient’s condition has stabilised.
Before initiating empagliflozin, factors in the patient history that may predispose to ketoacidosis should be considered.

Patients who may be at higher risk of DKA include patients with a low beta-cell function reserve (e.g. type 2 diabetes patients with low C-peptide or latent autoimmune diabetes in adults (LADA) or patients with a history of pancreatitis), patients with conditions that lead to restricted food intake or severe dehydration, patients for whom insulin doses are reduced and patients with increased insulin requirements due to acute medical illness, surgery or alcohol abuse. SGLT2 inhibitors should be used with caution in these patients.

Restarting SGLT2 inhibitor treatment in patients with previous DKA while on SGLT2 inhibitor treatment is not recommended, unless another clear precipitating factor is identified and resolved.

The safety and efficacy of empagliflozin in patients with type 1 diabetes have not been established and empagliflozin should not be used for treatment of patients with type 1 diabetes. Limited data from clinical trials suggest that DKA occurs with common frequency when patients with type 1 diabetes are treated with SGLT2 inhibitors.

Lactic acidosis

Lactic acidosis is a very rare, but serious (high mortality in the absence of prompt treatment), metabolic complication that can occur due to metformin accumulation. Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with renal failure or acute worsening of renal function. Special caution should be paid to situations where renal function may become impaired, for example in case of dehydration (severe diarrhoea or vomiting), or when initiating antihypertensive therapy or diuretic therapy and when starting therapy with a non-steroidal anti-inflammatory drug (NSAID). In the acute conditions listed, metformin should be temporarily discontinued.

Other associated risk factors should be considered to avoid lactic acidosis such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic impairment and any condition associated with hypoxia (such as decompensated cardiac failure, acute myocardial infarction) (see section 4.3).

The risk of lactic acidosis must be considered in the event of non-specific signs such as muscle cramps, digestive disorders as abdominal pain and severe asthenia. Patients should be instructed to notify these signs immediately to their physicians if they occur, notably if patients had a good tolerance to Synjardy before. Synjardy should be discontinued, at least temporarily, until the situation is clarified. Reintroduction of Synjardy should then be discussed taking into account the benefit/risk ratio in an individual basis as well as renal function.

Diagnosis

Lactic acidosis is characterised by acidotic dyspnea, abdominal pain and hypothermia followed by coma. Diagnostic laboratory findings are decreased blood pH, plasma lactate levels above 5 mmol/l, and an increased anion gap and lactate/pyruvate ratio. In case of lactic acidosis, the patient should be hospitalised immediately (see section 4.9).

Physicians should alert the patients on the risk and on the symptoms of lactic acidosis.

Renal impairment

Due to the mechanism of action, decreased renal function will result in reduced efficacy of empagliflozin. Metformin is excreted by the kidney. Therefore, serum creatinine levels should be determined before initiating treatment and regularly thereafter:

- at least annually in patients with normal renal function
• at least two to four times a year in patients with serum creatinine levels at the upper limit of normal and in elderly subjects
Decreased renal function in elderly patients is frequent and asymptomatic. Special caution should be exercised in situations where renal function may become impaired, for example in case of dehydration, or when initiating antihypertensive therapy or diuretic therapy and when starting therapy with a non-steroidal anti-inflammatory drug (NSAID).
In these cases, it is also recommended to check renal function before initiating treatment with Synjardy.

Cardiac function
Patients with heart failure are more at risk of hypoxia and renal insufficiency. In patients with stable chronic heart failure, Synjardy may be used with a regular monitoring of cardiac and renal function. For patients with acute and unstable heart failure, Synjardy is contraindicated due to the metformin component (see section 4.3).

Hepatic injury
Cases of hepatic injury have been reported with empagliflozin in clinical trials. A causal relationship between empagliflozin and hepatic injury has not been established.

Administration of iodinated contrast agent
The intravascular administration of iodinated contrast materials in radiologic studies can lead to renal failure. This may induce metformin accumulation and may increase the risk for lactic acidosis. Therefore, this medicinal product must be discontinued prior to, or at the time of the test and not be reinstated until at least 48 hours afterwards, and only after renal function has been re-evaluated and has not deteriorated further (see section 4.5).

Surgery
As this medicinal product contains metformin, the treatment must be discontinued 48 hours before elective surgery with general, spinal or peridural anaesthesia. Therapy should usually not be resumed earlier than 48 hours following surgery and only after renal function has been reevaluated and found to be normal.

Risk for volume depletion
Based on the mode of action of SGLT2 inhibitors, osmotic diuresis accompanying therapeutic glucosuria may lead to a modest decrease in blood pressure (see section 5.1). Therefore, caution should be exercised in patients for whom an empagliflozin-induced drop in blood pressure could pose a risk, such as patients with known cardiovascular disease, patients on anti-hypertensive therapy with a history of hypotension or patients aged 75 years and older.

In case of conditions that may lead to fluid loss (e.g. gastrointestinal illness), careful monitoring of volume status (e.g. physical examination, blood pressure measurements, laboratory tests including haematocrit) and electrolytes is recommended for patients receiving Synjardy. Temporary interruption of treatment with Synjardy should be considered until the fluid loss is corrected.

Urinary tract infections
The overall frequency of urinary tract infection reported as adverse event was higher in patients treated with empagliflozin 10 mg on a background of metformin compared to patients treated with placebo or empagliflozin 25 mg on a background of metformin (see section 4.8). Complicated urinary tract infection (e.g. pyelonephritis or urosepsis) occurred at a similar frequency in patients treated with empagliflozin compared to placebo. However, temporary interruption of treatment should be considered in patients with complicated urinary tract infections.
Elderly

The effect of empagliflozin on urinary glucose excretion is associated with osmotic diuresis, which could affect the hydration status. Patients aged 75 years and older may be at an increased risk of volume depletion. Therapeutic experience in patients aged 85 years and older is limited. Initiation of therapy in this population is not recommended (see section 4.2).

Cardiac failure

Experience in New York Heart Association (NYHA) class I-II is limited, and there is no experience in clinical studies with empagliflozin in NYHA class III-IV.

Urine laboratory assessments

Due to its mechanism of action, patients taking Synjardy will test positive for glucose in their urine.

4.5 Interaction with other medicinal products and other forms of interaction

Co-administration of multiple doses of empagliflozin and metformin does not meaningfully alter the pharmacokinetics of either empagliflozin or metformin in healthy subjects.

No interaction studies have been performed for Synjardy. The following statements reflect the information available on the individual active substances.

Empagliflozin

Pharmacodynamic interactions

Diuretics
As Synjardy contains empagliflozin it may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension (see section 4.4).

Insulin and insulin secretagogues
Insulin and insulin secretagogues, such as sulphonylureas, may increase the risk of hypoglycaemia. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with empagliflozin (see sections 4.2 and 4.8).

Pharmacokinetic interactions

Effects of other medicinal products on empagliflozin
In vitro data suggest that the primary route of metabolism of empagliflozin in humans is glucuronidation by uridine 5'-diphosphoglucuronosyltransferases UGT1A3, UGT1A8, UGT1A9, and UGT2B7. Empagliflozin is a substrate of the human uptake transporters OAT3, OATP1B1, and OATP1B3, but not OAT1 and OCT2. Empagliflozin is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).

Co-administration of empagliflozin with probenecid, an inhibitor of UGT enzymes and OAT3, resulted in a 26% increase in peak empagliflozin plasma concentrations (C_{max}) and a 53% increase in area under the concentration-time curve (AUC). These changes were not considered to be clinically meaningful.

The effect of UGT induction on empagliflozin has not been studied. Co-medication with known inducers of UGT enzymes should be avoided due to a potential risk of decreased efficacy.
An interaction study with gemfibrozil, an in vitro inhibitor of OAT3 and OATP1B1/1B3 transporters, showed that empagliflozin C\textsubscript{max} increased by 15% and AUC increased by 59% following co-administration. These changes were not considered to be clinically meaningful.

Inhibition of OATP1B1/1B3 transporters by co-administration with rifampicin resulted in a 75% increase in C\textsubscript{max} and a 35% increase in AUC of empagliflozin. These changes were not considered to be clinically meaningful.

Empagliflozin exposure was similar with and without co-administration with verapamil, a P-gp inhibitor, indicating that inhibition of P-gp does not have any clinically relevant effect on empagliflozin.

Interaction studies conducted in healthy volunteers suggest that the pharmacokinetics of empagliflozin were not influenced by co-administration with metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin, verapamil, ramipril, simvastatin, torasemide and hydrochlorothiazide.

**Effects of empagliflozin on other medicinal products**

Based on in vitro studies, empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms. Empagliflozin does not inhibit UGT1A1, UGT1A3, UGT1A8, UGT1A9, or UGT2B7. Drug-drug interactions involving the major CYP450 and UGT isoforms with empagliflozin and concomitantly administered substrates of these enzymes are therefore considered unlikely.

Empagliflozin does not inhibit P-gp at therapeutic doses. Based on in vitro studies, empagliflozin is considered unlikely to cause interactions with medicinal products that are P-gp substrates. Co-administration of digoxin, a P-gp substrate, with empagliflozin resulted in a 6% increase in AUC and 14% increase in C\textsubscript{max} of digoxin. These changes were not considered to be clinically meaningful.

Empagliflozin does not inhibit human uptake transporters such as OAT3, OATP1B1, and OATP1B3 in vitro at clinically relevant plasma concentrations and, as such, drug-drug interactions with substrates of these uptake transporters are considered unlikely.

Interaction studies conducted in healthy volunteers suggest that empagliflozin had no clinically relevant effect on the pharmacokinetics of metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, simvastatin, warfarin, ramipril, digoxin, diuretics and oral contraceptives.

**Metformin**

*Combinations not recommended*

There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic impairment due to the metformin active substance (see section 4.4)). Consumption of alcohol and medicinal products containing alcohol should be avoided.

Cationic substances that are eliminated by renal tubular secretion (e.g. cimetidine) may interact with metformin by competing for common renal tubular transport systems.

The intravascular administration of iodinated contrast agents in radiological studies may lead to renal failure, resulting in metformin accumulation and a risk of lactic acidosis. Therefore, this medicinal product must be discontinued prior to, or at the time of the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and has not deteriorated further (see section 4.4).

*Combination requiring precautions for use*

Glucocorticoids (given by systemic and local routes), beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity. The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment with such medicinal products. If necessary, the dose of the anti-hyperglycaemic medicinal product should be adjusted during therapy with the other medicinal product and on its discontinuation.
**Insulin and insulin secretagogues**

Insulin and insulin secretagogues, such as sulphonylureas, may increase the risk of hypoglycaemia. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with metformin (see sections 4.2 and 4.8).

### 4.6 Fertility, pregnancy and lactation

#### Pregnancy

There are no data from the use of this medicinal product or empagliflozin in pregnant women. Animal studies show that empagliflozin crosses the placenta during late gestation to a very limited extent but do not indicate direct or indirect harmful effects with respect to early embryonic development. However, animal studies have shown adverse effects on postnatal development. A limited amount of data suggests that the use of metformin in pregnant women is not associated with an increased risk of congenital malformations. Animal studies with the combination of empagliflozin and metformin or with metformin alone have shown reproductive toxicity at higher doses of metformin only (see section 5.3).

When the patient plans to become pregnant, and during pregnancy, it is recommended that diabetes is not treated with this medicinal product, but insulin be used to maintain blood glucose levels as close to normal as possible, to reduce the risk of malformations of the foetus associated with abnormal blood glucose levels.

#### Breast-feeding

Metformin is excreted into human milk. No effects have been shown in breastfed newborns/infants of treated women. No data in humans are available on excretion of empagliflozin into milk. Available animal data have shown excretion of empagliflozin and metformin in milk. A risk to the newborns/infants cannot be excluded.

This medicinal product should not be used during breast feeding.

#### Fertility

No studies on the effect on human fertility have been conducted for this medicinal product or empagliflozin. Animal studies with empagliflozin and metformin do not indicate direct or indirect harmful effects with respect to fertility (see section 5.3).

### 4.7 Effects on ability to drive and use machines

Synjardy has minor influence on the ability to drive and use machines. Patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines, in particular when Synjardy is used in combination with a sulphonylurea and/or insulin.

### 4.8 Undesirable effects

#### Summary of the safety profile

A total of 7052 patients with type 2 diabetes were treated in clinical studies to evaluate the safety of empagliflozin as add-on to metformin, of which 4740 patients were treated with empagliflozin as add-on to metformin.

Placebo controlled double-blinded trials of 18 to 24 weeks of exposure included 3456 patients, of which 1271 were treated with empagliflozin 10 mg as add-on to metformin and 1259 with empagliflozin 25 mg as add-on to metformin. The most commonly reported adverse events in clinical trials were hypoglycaemia in combination with insulin and/or sulphonylurea, urinary tract infections,
genital tract infections and increased urination (see description of selected side effects). No additional adverse reactions were identified in clinical trials with empagliflozin as add-on to metformin compared to the side effects of the single components.

Tabulated list of adverse reactions

The adverse reactions are listed by absolute frequency. Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), or very rare (<1/10,000), and not known (cannot be estimated from the available data).

Table 1 Adverse reactions reported in placebo-controlled studies

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Very common</th>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
<th>Very rare</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infections and infestations</strong></td>
<td></td>
<td>Vaginal moniliasis, vulvovaginitis, balanitis and other genital infection(^1,2)</td>
<td>Urinary tract infection(^1,2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td>Hypoglycaemia (when used with sulphonylurea or insulin)(^1)</td>
<td></td>
<td></td>
<td>Diabetic ketoacidosis(^a, b)</td>
<td>Lactic acidosis(^3) Vitamin B12 deficiency(^3, 4)</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td>Taste disturbance(^3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td>Volume depletion(^1, 2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td>Gastrointestinal symptoms(^3, 5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td>Liver function tests abnormalities(^3) Hepatitis(^3)</td>
<td></td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td>Pruritus (generalised)</td>
<td></td>
<td></td>
<td>Erythema(^3) Urticaria(^1)</td>
<td></td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td>Increased urination(^1, 2)</td>
<td></td>
<td>Dysuria(^2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) See subsections below for additional information
\(^2\) Identified adverse reactions of empagliflozin monotherapy
\(^3\) Identified adverse reactions of metformin monotherapy
\(^4\) Long-term treatment with metformin has been associated with a decrease in vitamin B12 absorption which may very rarely result in clinically significant vitamin B12 deficiency (e.g. megaloblastic anaemia)
\(^5\) Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite occur most frequently during initiation of therapy and resolve spontaneously in most cases.
\(^a\) derived from postmarketing experience
\(^b\) see section 4.4

Description of selected adverse reactions

*Hypoglycaemia*

The frequency of hypoglycaemia depended on the background therapy in the respective studies.
**Overall hypoglycaemia**
The frequency of patients with hypoglycaemic events was similar for empagliflozin and placebo as add-on to metformin. An increased frequency was noted when empagliflozin given as add-on to metformin and a sulfonylurea (empagliflozin 10 mg: 16.1%, empagliflozin 25 mg: 11.5% and placebo: 8.4%) or as add-on to metformin and insulin (empagliflozin 10 mg: 31.3%, empagliflozin 25 mg: 36.2% and placebo: 34.7%).

**Major hypoglycaemia (hypoglycaemia requiring assistance)**
The frequency of patients with major hypoglycaemic events was low (<1%) and similar for empagliflozin and placebo as add-on to metformin. Major hypoglycaemic events occurred in 0.5%, 0% and 0.5% of patients treated with empagliflozin 10 mg, empagliflozin 25 mg and placebo when added on to metformin and insulin, respectively. No patient had a major hypoglycaemic event in the combination with metformin and a sulphonylurea.

**Urinary tract infection**
The overall frequency of urinary tract infection adverse events was higher in metformin-treated patients who received empagliflozin 10 mg (8.8%) compared to empagliflozin 25 mg (6.6%) or placebo (7.8%). Similar to placebo, urinary tract infection was reported more frequently for empagliflozin in patients with a history of chronic or recurrent urinary tract infections. The intensity of urinary tract infections (i.e., mild/moderate/severe) was similar to placebo. Urinary tract infection events were reported more frequently for empagliflozin 10 mg compared with placebo in female patients, but not for empagliflozin 25 mg. The frequencies of urinary tract infections were low for male patients and were balanced across treatment groups.

**Vaginal moniliasis, vulvovaginitis, balanitis and other genital infection**
Vaginal moniliasis, vulvovaginitis, balanitis and other genital infections were reported more frequently in metformin-treated patients who received empagliflozin 10 mg (4.0%) and empagliflozin 25 mg (3.9%) compared to placebo (1.3%), and were reported more frequently for empagliflozin compared to placebo in female patients. The difference in frequency was less pronounced in male patients. Genital tract infections were mild and moderate in intensity, none was severe in intensity.

**Increased urination**
As expected from the mechanism of action, increased urination (as assessed by PT search including pollakiuria, polyuria, nocturia) was observed at higher frequencies in metformin-treated patients who received empagliflozin 10 mg (3.0%) and empagliflozin 25 mg (2.9%) compared to placebo (1.4%) as add-on to metformin therapy. Increased urination was mostly mild or moderate in intensity. The frequency of reported nocturia was comparable between placebo and empagliflozin (<1%).

**Volume depletion**
The overall frequency of volume depletion (including the predefined terms blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolaemia, orthostatic hypotension, and syncope) in metformin-treated patients who received empagliflozin was low: 0.6% for empagliflozin 10 mg, 0.3% for empagliflozin 25 mg and 0.1% for placebo. The effect of empagliflozin on urinary glucose excretion is associated with osmotic diuresis, which could affect hydration status of patients age 75 years and older. In patients ≥75 years of age volume depletion events have been reported in a single patient treated with empagliflozin 25 mg as add-on to metformin therapy.

**Reporting of suspected adverse reactions**
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
4.9 Overdose

Symptoms

**Empagliflozin**
In controlled clinical studies single doses of up to 800 mg empagliflozin (equivalent to 32-times the highest recommended daily dose) in healthy volunteers and multiple daily doses of up to 100 mg empagliflozin (equivalent to 4-times the highest recommended daily dose) in patients with type 2 diabetes did not show any toxicity. Empagliflozin increased urine glucose excretion leading to an increase in urine volume. The observed increase in urine volume was not dose-dependent and is not clinically meaningful. There is no experience with doses above 800 mg in humans.

**Metformin**
Hypoglycaemia has not been seen with metformin doses of up to 85 g, although lactic acidosis has occurred in such circumstances. High overdose of metformin or concomitant risks may lead to lactic acidosis. Lactic acidosis is a medical emergency and must be treated in hospital.

**Therapy**
In the event of an overdose, treatment should be initiated as appropriate to the patient's clinical status. The most effective method to remove lactate and metformin is haemodialysis. The removal of empagliflozin by haemodialysis has not been studied.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs, ATC code: A10BD20

**Mechanism of action**

Synjardy combines two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: empagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2), and metformin hydrochloride, a member of the biguanide class.

**Empagliflozin**
Empagliflozin is a reversible, highly potent (IC$_{50}$ of 1.3 nmol) and selective competitive inhibitor of SGLT2. Empagliflozin does not inhibit other glucose transporters important for glucose transport into peripheral tissues and is 5000-times more selective for SGLT2 versus SGLT1, the major transporter responsible for glucose absorption in the gut. SGLT2 is highly expressed in the kidney, whereas expression in other tissues is absent or very low. It is responsible, as the predominant transporter, for the reabsorption of glucose from the glomerular filtrate back into the circulation. In patients with type 2 diabetes and hyperglycaemia a higher amount of glucose is filtered and reabsorbed.

Empagliflozin improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption. The amount of glucose removed by the kidney through this glucuretic mechanism is dependent on blood glucose concentration and GFR. Inhibition of SGLT2 in patients with type 2 diabetes and hyperglycaemia leads to excess glucose excretion in the urine.

In patients with type 2 diabetes, urinary glucose excretion increased immediately following the first dose of empagliflozin and is continuous over the 24 hour dosing interval. Increased urinary glucose excretion was maintained at the end of the 4-week treatment period, averaging approximately 78 g/day.
with empagliflozin 25 mg. Increased urinary glucose excretion resulted in an immediate reduction in plasma glucose levels in patients with type 2 diabetes.

Empagliflozin improves both fasting and post-prandial plasma glucose levels. The mechanism of action of empagliflozin is independent of beta cell function and insulin pathway and this contributes to a low risk of hypoglycaemia. Improvement of surrogate markers of beta cell function including Homeostasis Model Assessment-β (HOMA-β) was noted. In addition, urinary glucose excretion triggers calorie loss, associated with body fat loss and body weight reduction. The glucosuria observed with empagliflozin is accompanied by mild diuresis which may contribute to sustained and moderate reduction of blood pressure.

**Metformin**

Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.

Metformin may act via 3 mechanisms:

- reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis,
- in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilization,
- and delay of intestinal glucose absorption.

Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase. Metformin increases the transport capacity of all types of membrane glucose transporters (GLUTs) known to date.

In humans, independently of its action on glycaemia, metformin has favourable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies: metformin reduces total cholesterol, LDL cholesterol and triglyceride levels.

**Clinical efficacy and safety**

A total of 4704 patients with type 2 diabetes were treated in 7 double-blind, placebo or active-controlled clinical studies of at least 24 weeks duration, of which 1109 patients received empagliflozin 10 mg and 1863 received empagliflozin 25 mg as add-on to metformin therapy. Of these, a total of 530 patients received empagliflozin as add-on to metformin plus insulin, of which 266 patients were treated with empagliflozin 10 mg and 264 with empagliflozin 25 mg.

Treatment with empagliflozin in combination with metformin with or without other antidiabetic medicinal products (pioglitazone, sulfonylurea, DPP-4 inhibitors, and insulin) led to clinically relevant improvements in HbA1c, fasting plasma glucose (FPG), body weight, systolic and diastolic blood pressure. Administration of empagliflozin 25 mg resulted in a higher proportion of patients achieving HbA1c goal of less than 7% and fewer patients needing glycaemic rescue compared to empagliflozin 10 mg and placebo. In patients age 75 years and older, numerically lower reductions in HbA1c were observed with empagliflozin treatment. Higher baseline HbA1c was associated with a greater reduction in HbA1c.

**Empagliflozin as add-on to metformin, sulphonylurea, pioglitazone**

Empagliflozin as add-on to metformin, metformin and a sulphonylurea, or pioglitazone and metformin resulted in statistically significant (p<0.0001) reductions in HbA1c and body weight compared to placebo (Table 2). In addition it resulted in a clinically meaningful reduction in FPG, systolic and diastolic blood pressure compared to placebo.

In the double-blind placebo-controlled extension of these studies, reduction of HbA1c, body weight and blood pressure were sustained up to Week 76.
Table 2: Efficacy results of 24 week placebo-controlled studies

<table>
<thead>
<tr>
<th>Add-on to metformin therapy (^a)</th>
<th>Placebo</th>
<th>Empagliflozin 10 mg</th>
<th>Empagliflozin 25 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>207</td>
<td>217</td>
<td>213</td>
</tr>
<tr>
<td><strong>HbA1c (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>7.90</td>
<td>7.94</td>
<td>7.86</td>
</tr>
<tr>
<td>Change from baseline (^1)</td>
<td>-0.13</td>
<td>-0.70</td>
<td>-0.77</td>
</tr>
<tr>
<td>Difference from placebo (^1)</td>
<td>-0.57*  (-0.72, -0.42)</td>
<td>-0.64* (-0.79, -0.48)</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>184</td>
<td>199</td>
<td>191</td>
</tr>
<tr>
<td><strong>Patients (%) achieving</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c &lt;7% with baseline  HbA1c ≥7% (^2)</td>
<td>12.5</td>
<td>37.7</td>
<td>38.7</td>
</tr>
<tr>
<td>N</td>
<td>207</td>
<td>217</td>
<td>213</td>
</tr>
<tr>
<td><strong>Body Weight (kg)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>79.73</td>
<td>81.59</td>
<td>82.21</td>
</tr>
<tr>
<td>Change from baseline (^1)</td>
<td>-0.45</td>
<td>-2.08</td>
<td>-2.46</td>
</tr>
<tr>
<td>Difference from placebo (^1)</td>
<td>-1.63*  (-2.17, -1.08)</td>
<td>-2.01* (-2.56, -1.46)</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>207</td>
<td>217</td>
<td>213</td>
</tr>
<tr>
<td><strong>SBP (mmHg)(^2)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>128.6</td>
<td>129.6</td>
<td>130.0</td>
</tr>
<tr>
<td>Change from baseline (^1)</td>
<td>-0.4</td>
<td>-4.5</td>
<td>-5.2</td>
</tr>
<tr>
<td>Difference from placebo (^1)</td>
<td>-4.1*   (-6.2, -2.1)</td>
<td>-4.8* (-6.9, -2.7)</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>225</td>
<td>225</td>
<td>216</td>
</tr>
</tbody>
</table>

Add-on to metformin and a sulphonylurea therapy \(^a\)

<table>
<thead>
<tr>
<th>Placebo</th>
<th>Empagliflozin 10 mg</th>
<th>Empagliflozin 25 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>225</td>
<td>225</td>
</tr>
<tr>
<td><strong>HbA1c (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>8.15</td>
<td>8.07</td>
</tr>
<tr>
<td>Change from baseline (^1)</td>
<td>-0.17</td>
<td>-0.82</td>
</tr>
<tr>
<td>Difference from placebo (^1)</td>
<td>-0.64*  (-0.79, -0.49)</td>
<td>-0.59* (-0.74, -0.44)</td>
</tr>
<tr>
<td>N</td>
<td>216</td>
<td>209</td>
</tr>
<tr>
<td><strong>Patients (%) achieving</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c &lt;7% with baseline  HbA1c ≥7% (^2)</td>
<td>9.3</td>
<td>26.3</td>
</tr>
<tr>
<td>N</td>
<td>225</td>
<td>225</td>
</tr>
<tr>
<td><strong>Body Weight (kg)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>76.23</td>
<td>77.08</td>
</tr>
<tr>
<td>Change from baseline (^1)</td>
<td>-0.39</td>
<td>-2.16</td>
</tr>
<tr>
<td>Difference from placebo (^1)</td>
<td>-1.76*  (-2.25, -1.28)</td>
<td>-1.99* (-2.48, -1.50)</td>
</tr>
<tr>
<td>N</td>
<td>225</td>
<td>225</td>
</tr>
<tr>
<td><strong>SBP (mmHg)(^2)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>128.8</td>
<td>128.7</td>
</tr>
<tr>
<td>Change from baseline (^1)</td>
<td>-1.4</td>
<td>-4.1</td>
</tr>
<tr>
<td>Difference from placebo (^1)</td>
<td>-2.7    (-4.6, -0.8)</td>
<td>-2.1 (-4.0, -0.2)</td>
</tr>
</tbody>
</table>
Empagliflozin 24 months data, as add-on to metformin in comparison to glimepiride

In a study comparing the efficacy and safety of empagliflozin 25 mg versus glimepiride (up to 4 mg per day) in patients with inadequate glycaemic control on metformin alone, treatment with empagliflozin daily resulted in superior reduction in HbA1c (Table 3), and a clinically meaningful reduction in FPG, compared to glimepiride. Empagliflozin daily resulted in a statistically significant reduction in body weight, systolic and diastolic blood pressure and a statistically significantly lower proportion of patients with hypoglycaemic events compared to glimepiride (2.5% for empagliflozin, 24.2% for glimepiride, p<0.0001).

<table>
<thead>
<tr>
<th>Add-on to pioglitazone + metformin therapy&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Placebo</th>
<th>10 mg</th>
<th>25 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>124</td>
<td>125</td>
<td>127</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>8.15</td>
<td>8.07</td>
<td>8.10</td>
</tr>
<tr>
<td>Change from baseline&lt;sup&gt;1&lt;/sup&gt;</td>
<td>-0.11</td>
<td>-0.55</td>
<td>-0.70</td>
</tr>
<tr>
<td>Difference from placebo&lt;sup&gt;1&lt;/sup&gt; (97.5% CI)</td>
<td>-0.45* (-0.69, -0.21)</td>
<td>-0.60* (-0.83, -0.36)</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>118</td>
<td>116</td>
<td>123</td>
</tr>
<tr>
<td>Patients (%) achieving HbA1c &lt;7% with baseline HbA1c ≥7%&lt;sup&gt;2&lt;/sup&gt;</td>
<td>8.5</td>
<td>22.4</td>
<td>28.5</td>
</tr>
<tr>
<td>N</td>
<td>124</td>
<td>125</td>
<td>127</td>
</tr>
<tr>
<td>Body Weight (kg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>79.45</td>
<td>79.44</td>
<td>80.98</td>
</tr>
<tr>
<td>Change from baseline&lt;sup&gt;1&lt;/sup&gt;</td>
<td>0.40</td>
<td>-1.74</td>
<td>-1.59</td>
</tr>
<tr>
<td>Difference from placebo&lt;sup&gt;1&lt;/sup&gt; (97.5% CI)</td>
<td>-2.14* (-2.93, -1.35)</td>
<td>-2.00* (-2.78, -1.21)</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>124</td>
<td>125</td>
<td>127</td>
</tr>
<tr>
<td>SBP (mmHg)&lt;sup&gt;2&lt;/sup&gt;,&lt;sup&gt;3&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>125.5</td>
<td>126.3</td>
<td>126.3</td>
</tr>
<tr>
<td>Change from baseline&lt;sup&gt;1&lt;/sup&gt;</td>
<td>0.8</td>
<td>-3.5</td>
<td>-3.3</td>
</tr>
<tr>
<td>Difference from placebo&lt;sup&gt;1&lt;/sup&gt; (95% CI)</td>
<td>-4.2** (-6.94, -1.53)</td>
<td>-4.1** (-6.76, -1.37)</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Full analysis set (FAS) using last observation carried forward (LOCF) prior to glycaemic rescue therapy

<sup>b</sup> Subgroup analysis for patients on additional background of metformin (FAS, LOCF)

<sup>1</sup> Mean adjusted for baseline value

<sup>2</sup> Not evaluated for statistical significance as a part of the sequential confirmatory testing procedure

<sup>3</sup> LOCF, values after antihypertensive rescue censored

* p-value <0.0001

** p-value <0.01
Table 3: Efficacy results at 104 week in an active controlled study comparing empagliflozin to glimepiride as add on to metformin

<table>
<thead>
<tr>
<th></th>
<th>Empagliflozin 25 mg</th>
<th>Glimepiride b</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>765</td>
<td>780</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>7.92</td>
<td>7.92</td>
</tr>
<tr>
<td>Change from baseline c</td>
<td>-0.66</td>
<td>-0.55</td>
</tr>
<tr>
<td>Difference from glimepiride c (97.5% CI)</td>
<td>-0.11* (-0.20, -0.01)</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>690</td>
<td>715</td>
</tr>
<tr>
<td>Patients (%) achieving HbA1c &lt;7% with baseline HbA1c ≥7% d</td>
<td>33.6</td>
<td>30.9</td>
</tr>
<tr>
<td>N</td>
<td>765</td>
<td>780</td>
</tr>
<tr>
<td>Body Weight (kg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>82.52</td>
<td>83.03</td>
</tr>
<tr>
<td>Change from baseline c</td>
<td>-3.12</td>
<td>1.34</td>
</tr>
<tr>
<td>Difference from glimepiride c (97.5% CI)</td>
<td>-4.46** (-4.87, -4.05)</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>765</td>
<td>780</td>
</tr>
<tr>
<td>SBP (mmHg) e</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>133.4</td>
<td>133.5</td>
</tr>
<tr>
<td>Change from baseline c</td>
<td>-3.1</td>
<td>2.5</td>
</tr>
<tr>
<td>Difference from glimepiride c (97.5% CI)</td>
<td>-5.6** (-7.0, -4.2)</td>
<td></td>
</tr>
</tbody>
</table>

a Full analysis set (FAS) using last observation carried forward (LOCF) prior to glycaemic rescue therapy
b Up to 4 mg glimepiride
c Mean adjusted for baseline value
d Not evaluated for statistical significance as a part of the sequential confirmatory testing procedure
e LOCF, values after antihypertensive rescue censored
* p-value <0.0001 for non-inferiority, and p-value = 0.0153 for superiority
** p-value <0.0001

Add-on to insulin therapy
Empagliflozin as add-on to multiple daily insulin
The efficacy and safety of empagliflozin as add-on to multiple daily insulin with concomitant metformin therapy was evaluated in a double-blind, placebo-controlled trial of 52 weeks duration. During the initial 18 weeks and the last 12 weeks, the insulin dose was kept stable, but was adjusted to achieve pre-prandial glucose levels <100 mg/dl [5.5 mmol/l], and post-prandial glucose levels <140 mg/dl [7.8 mmol/l] between Weeks 19 and 40.
At Week 18, empagliflozin provided statistically significant improvement in HbA1c compared with placebo (Table 4).
At Week 52, treatment with empagliflozin resulted in a statistically significant decrease in HbA1c and insulin sparing compared with placebo and a reduction in body weight.
Table 4: Efficacy results at 18 and 52 weeks in a placebo-controlled study of empagliflozin as add-on to multiple daily doses of insulin with concomitant metformin therapy

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>empagliflozin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10 mg</td>
<td>25 mg</td>
</tr>
<tr>
<td>N</td>
<td>135</td>
<td>128</td>
</tr>
<tr>
<td>HbA1c (%) at week 18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>8.29</td>
<td>8.42</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>-0.58</td>
<td>-0.99</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-0.41*</td>
<td>-0.45*</td>
</tr>
<tr>
<td>(97.5% CI)</td>
<td>(-0.61, -0.21)</td>
<td>(-0.65, -0.25)</td>
</tr>
<tr>
<td>N</td>
<td>86</td>
<td>84</td>
</tr>
<tr>
<td>HbA1c (%) at week 52</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>8.26</td>
<td>8.43</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>-0.86</td>
<td>-1.23</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-0.37**</td>
<td>-0.45*</td>
</tr>
<tr>
<td>(97.5% CI)</td>
<td>(-0.67, -0.08)</td>
<td>(-0.74, -0.16)</td>
</tr>
<tr>
<td>N</td>
<td>84</td>
<td>84</td>
</tr>
<tr>
<td>Patients (%) achieving</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c &lt;7% with</td>
<td></td>
<td></td>
</tr>
<tr>
<td>baseline HbA1c ≥7% at</td>
<td></td>
<td></td>
</tr>
<tr>
<td>week 52</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>27.4</td>
<td>41.7</td>
</tr>
<tr>
<td>N</td>
<td>86</td>
<td>83</td>
</tr>
<tr>
<td>Insulin dose (IU/day)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>at week 52</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>91.01</td>
<td>91.77</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>12.84</td>
<td>0.22</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-12.61**</td>
<td>-15.09**</td>
</tr>
<tr>
<td>(97.5% CI)</td>
<td>(-21.43, -3.80)</td>
<td>(-23.79, -6.40)</td>
</tr>
<tr>
<td>N</td>
<td>86</td>
<td>84</td>
</tr>
<tr>
<td>Body Weight (kg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>at week 52</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>97.78</td>
<td>98.86</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>0.42</td>
<td>-2.47</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-2.89*</td>
<td>-2.37*</td>
</tr>
<tr>
<td>(97.5% CI)</td>
<td>(-4.29, -1.49)</td>
<td>(-3.75, -0.98)</td>
</tr>
</tbody>
</table>

Subgroup analysis for patients on additional background of metformin (FAS, LOCF)
Subgroup analysis for patients on additional background of metformin (PPS-Completers, LOCF)
Mean adjusted for baseline value
not evaluated for statistical significance as a part of the sequential confirmatory testing procedure
Week 19-40: treat-to-target regimen for insulin dose adjustment to achieve pre-defined glucose target levels (pre-prandial <100 mg/dl (5.5 mmol/l), post-prandial <140 mg/dl (7.8 mmol/l)
* p-value ≤0.0005
** p-value <0.005

Empagliflozin as add on to basal insulin

The efficacy and safety of empagliflozin as add on to basal insulin with concomitant metformin therapy was evaluated in a double-blind, placebo-controlled trial of 78 weeks duration. During the initial 18 weeks the insulin dose was kept stable, but was adjusted to achieve a FPG <110 mg/dl in the following 60 weeks.

At week 18, empagliflozin provided statistically significant improvement in HbA1c. A greater proportion of patients treated with empagliflozin and with a baseline HbA1c ≥7.0% achieved a target HbA1c of <7% compared to placebo (Table 5).

At 78 weeks, the decrease in HbA1c and insulin sparing effect of empagliflozin was maintained. Furthermore, empagliflozin resulted in a reduction in FPG, body weight and blood pressure.
Table 5  Efficacy results at 18 and 78 weeks in a placebo-controlled study of empagliflozin as add on to basal insulin with metformin

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Empagliflozin 10 mg</th>
<th>Empagliflozin 25 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>96</td>
<td>107</td>
<td>99</td>
</tr>
<tr>
<td><strong>HbA1c (%) at week 18</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>8.02</td>
<td>8.21</td>
<td>8.35</td>
</tr>
<tr>
<td>Change from baseline(^1)</td>
<td>-0.09</td>
<td>-0.62</td>
<td>-0.72</td>
</tr>
<tr>
<td>Difference from placebo(^1) (97.5% CI)</td>
<td>-0.54* (-0.77, -0.30)</td>
<td>-0.63* (-0.88, -0.39)</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>89</td>
<td>105</td>
<td>94</td>
</tr>
<tr>
<td><strong>HbA1c (%) at week 78</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>8.03</td>
<td>8.24</td>
<td>8.29</td>
</tr>
<tr>
<td>Change from baseline(^1)</td>
<td>-0.08</td>
<td>-0.42</td>
<td>-0.71</td>
</tr>
<tr>
<td>Difference from placebo(^1) (97.5% CI)</td>
<td>-0.34** (-0.64, -0.05)</td>
<td>-0.63* (-0.93, -0.33)</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>89</td>
<td>105</td>
<td>94</td>
</tr>
<tr>
<td><strong>Basal insulin dose (IU/day) at week 78</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>49.61</td>
<td>47.25</td>
<td>49.37</td>
</tr>
<tr>
<td>Change from baseline(^1)</td>
<td>4.14</td>
<td>-2.07</td>
<td>-0.28</td>
</tr>
<tr>
<td>Difference from placebo(^1) (97.5% CI)</td>
<td>-6.21** (-11.81, -0.61)</td>
<td>-4.42 (-10.18, 1.34)</td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) mean adjusted for baseline value
* p-value <0.0001
** p-value ≤0.025

**Empagliflozin and linagliptin as add-on therapy to metformin**

In a double-blind trial in patients with inadequate glycemic control, 24-weeks treatment with both doses of empagliflozin plus linagliptin as add-on to metformin therapy provided statistically significant (p<0.0001) reductions in HbA1c (change from baseline of -1.08% for empagliflozin 10 mg plus linagliptin 5 mg, -1.19% for empagliflozin 25 mg plus linagliptin 5 mg, -0.70% for linagliptin 5 mg). Compared to linagliptin 5 mg, both doses of empagliflozin plus linagliptin 5 mg provided statistically significant reductions in FPG and blood pressure. Both doses provided similar statistically significant reductions in body weight, expressed as kg and percentage change. A greater proportion of patients with a baseline HbA1c ≥7.0% and treated with empagliflozin plus linagliptin achieved a target HbA1c of <7% compared to linagliptin 5 mg. Clinically meaningful reductions in HbA1c were maintained for 52 weeks.

**Empagliflozin twice daily versus once daily as add on to metformin therapy**

The efficacy and safety of empagliflozin twice daily versus once daily (daily dose of 10 mg and 25 mg) as add-on therapy in patients with in sufficient glycemic control on metformin monotherapy was evaluated in a double blind placebo-controlled study of 16 weeks duration. All treatments with empagliflozin resulted in significant reductions in HbA1c from baseline (total mean 7.8%) after 16 weeks of treatment compared with placebo. Empagliflozin twice daily dose regimens on a background of metformin led to comparable reductions in HbA1c versus once daily dose regimens with a treatment difference in HbA1c reductions from baseline to week 16 of -0.02% (95% CI -0.16, 0.13) for empagliflozin 5 mg twice daily versus 10 mg once daily, and -0.11% (95% CI -0.26, 0.03) for empagliflozin 12.5 mg twice daily versus 25 mg once daily.

**Cardiovascular safety**

In a prospective, pre-specified meta-analysis of independently adjudicated cardiovascular events from 12 phase 2 and 3 clinical studies involving 10,036 patients with type 2 diabetes, empagliflozin did not increase cardiovascular risk.
**2 hour post-prandial glucose**

Treatment with empagliflozin as add-on to metformin or metformin plus sulfonylurea resulted in clinically meaningful improvement of 2-hour post-prandial glucose (meal tolerance test) at 24 weeks (add-on to metformin, placebo: +5.9 mg/dl, empagliflozin 10 mg: -46.0 mg/dl, empagliflozin 25 mg: -44.6 mg/dl; add-on to metformin plus sulphonylurea, placebo: -2.3 mg/dl, empagliflozin 10 mg: -35.7 mg/dl, empagliflozin 25 mg: -36.6 mg/dl).

**Patients with baseline HbA1c ≥9%**

In a pre-specified analysis of subjects with baseline HbA1c ≥9.0%, treatment with empagliflozin 10 mg or 25 mg as add-on to metformin resulted in statistically significant reductions in HbA1c at Week 24 (adjusted mean change from baseline of -1.49% for empagliflozin 25 mg, -1.40% for empagliflozin 10 mg, and -0.44% for placebo).

**Body weight**

In a pre-specified pooled analysis of 4 placebo controlled studies, treatment with empagliflozin (68% of all patients were on metformin background) resulted in body weight reduction compared to placebo at week 24 (-2.04 kg for empagliflozin 10 mg, -2.26 kg for empagliflozin 25 mg and -0.24 kg for placebo) that was maintained up to week 52 (-1.96 kg for empagliflozin 10 mg, -2.25 kg for empagliflozin 25 mg and -0.16 kg for placebo).

**Blood pressure**

The efficacy and safety of empagliflozin was evaluated in a double-blind, placebo controlled study of 12 weeks duration in patients with type 2 diabetes and high blood pressure on different antidiabetic and up to 2 antihypertensive therapies. Treatment with empagliflozin once daily resulted in statistically significant improvement in HbA1c, and 24 hour mean systolic and diastolic blood pressure as determined by ambulatory blood pressure monitoring (Table 6). Treatment with empagliflozin provided reductions in seated SBP and DBP.

**Table 6**  Efficacy results at 12 week in a placebo-controlled study of empagliflozin in patients with type 2 diabetes and uncontrolled blood pressure

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>empagliflozin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>10 mg</td>
</tr>
<tr>
<td>N</td>
<td></td>
<td>271</td>
</tr>
<tr>
<td><strong>HbA1c (%) at week 12</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>7.90</td>
<td>7.87</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>0.03</td>
<td>-0.59</td>
</tr>
<tr>
<td>Difference from placebo (95% CI)</td>
<td>-0.62* (-0.72, -0.52)</td>
<td>-0.65* (-0.75, -0.55)</td>
</tr>
<tr>
<td><strong>24 hour SBP at week 12</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>131.72</td>
<td>131.34</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>0.48</td>
<td>-2.95</td>
</tr>
<tr>
<td>Difference from placebo (95% CI)</td>
<td>-3.44* (-4.78, -2.09)</td>
<td>-4.16* (-5.50, -2.83)</td>
</tr>
<tr>
<td><strong>24 hour DBP at week 12</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>75.16</td>
<td>75.13</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>0.32</td>
<td>-1.04</td>
</tr>
<tr>
<td>Difference from placebo (95% CI)</td>
<td>-1.36** (-2.15, -0.56)</td>
<td>-1.72* (-2.51, -0.93)</td>
</tr>
</tbody>
</table>

* Full analysis set (FAS)
1 LOCF, values after taking antidiabetic rescue therapy censored
2 Mean adjusted for baseline HbA1c, baseline eGFR, geographical region and number of antihypertensive medicinal products
3 LOCF, values after taking antidiabetic rescue therapy or changing antihypertensive rescue therapy censored
In a pre-specified pooled analysis of 4 placebo-controlled studies, treatment with empagliflozin (68% of all patients were on metformin background) resulted in a reduction in systolic blood pressure (empagliflozin 10 mg: -3.9 mmHg, empagliflozin 25 mg: -4.3 mmHg) compared with placebo (-0.5 mmHg), and in diastolic blood pressure (empagliflozin 10 mg: -1.8 mmHg, empagliflozin 25 mg: -2.0 mmHg) compared with placebo (-0.5 mmHg), at week 24, that were maintained up to week 52.

Metformin
The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes. Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:

• a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1,000 patient-years) versus diet alone (43.3 events/1,000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p=0.0034,
• a significant reduction of the absolute risk of any diabetes-related mortality: metformin 7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017,
• a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patient-years (p=0.021),
• a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1,000 patient-years, diet alone 18 events/1,000 patient-years, (p=0.01).

Paediatric population
The European Medicines Agency has waived the obligation to submit the results of studies with Synjardy in all subsets of the paediatric population in type 2 diabetes (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties
Synjardy
The results of bioequivalence studies in healthy subjects demonstrated that Synjardy (empagliflozin/metformin hydrochloride) 5 mg/850 mg, 5 mg/1,000 mg, 12.5 mg/850 mg, and 12.5 mg/1,000 mg combination tablets are bioequivalent to co-administration of corresponding doses of empagliflozin and metformin as individual tablets.

Administration of empagliflozin/metformin 12.5 mg/1,000 mg under fed conditions resulted in 9% decrease in AUC and a 28% decrease in C_{max} for empagliflozin, when compared to fasted conditions. For metformin, AUC decreased by 12% and C_{max} decreased by 26% compared to fasting conditions. The observed effect of food on empagliflozin and metformin is not considered to be clinically relevant. However, as metformin is recommended to be given with meals, Synjardy is also proposed to be given with food.

The following statements reflect the pharmacokinetic properties of the individual active substances of Synjardy.
**Empagliflozin**

**Absorption**
The pharmacokinetics of empagliflozin have been extensively characterised in healthy volunteers and patients with type 2 diabetes. After oral administration, empagliflozin was rapidly absorbed with peak plasma concentrations occurring at a median t\(_{\text{max}}\) of 1.5 hours post-dose. Thereafter, plasma concentrations declined in a biphasic manner with a rapid distribution phase and a relatively slow terminal phase. The steady state mean plasma AUC and C\(_{\text{max}}\) were 1870 nmol.h and 259 nmol/l with empagliflozin 10 mg and 4740 nmol.h and 687 nmol/l with empagliflozin 25 mg once daily. Systemic exposure of empagliflozin increased in a dose-proportional manner. The single-dose and steady-state pharmacokinetic parameters of empagliflozin were similar suggesting linear pharmacokinetics with respect to time. There were no clinically relevant differences in empagliflozin pharmacokinetics between healthy volunteers and patients with type 2 diabetes.

The pharmacokinetics of 5 mg empagliflozin twice daily and 10 mg empagliflozin once daily were compared in healthy subjects. Overall exposure (AUC\(_{\text{ss}}\)) of empagliflozin over a 24-hour period with empagliflozin 5 mg administered twice daily was similar to empagliflozin 10 mg administered once daily. As expected, empagliflozin 5 mg administered twice daily compared with 10 mg empagliflozin once daily resulted in lower C\(_{\text{max}}\) and higher trough plasma empagliflozin concentrations (C\(_{\text{min}}\)).

Administration of empagliflozin 25 mg after intake of a high-fat and high calorie meal resulted in slightly lower exposure; AUC decreased by approximately 16% and C\(_{\text{max}}\) by approximately 37% compared to fasted condition. The observed effect of food on empagliflozin pharmacokinetics was not considered clinically relevant and empagliflozin may be administered with or without food. Similar results were obtained when Synjardy (empagliflozin/metformin) combination tablets were administered with high-fat and high calorie meal.

**Distribution**
The apparent steady-state volume of distribution was estimated to be 73.8 l based on the population pharmacokinetic analysis. Following administration of an oral [\(^{14}\)C]-empagliflozin solution to healthy volunteers, the red blood cell partitioning was approximately 37% and plasma protein binding was 86%.

**Biotransformation**
No major metabolites of empagliflozin were detected in human plasma, as defined by at least 10% of total drug-related material, and the most abundant metabolites were three glucuronide conjugates (2-, 3-, and 6-O-glucuronide). *In vitro* studies suggested that the primary route of metabolism of empagliflozin in humans is glucuronidation by the uridine 5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9.

**Elimination**
Based on the population pharmacokinetic analysis, the apparent terminal elimination half-life of empagliflozin was estimated to be 12.4 hours and apparent oral clearance was 10.6 l/hour. The inter-subject and residual variabilities for empagliflozin oral clearance were 39.1% and 35.8%, respectively. With once-daily dosing, steady-state plasma concentrations of empagliflozin were reached by the fifth dose. Consistent with the half-life, up to 22% accumulation, with respect to plasma AUC, was observed at steady-state. Following administration of an oral [\(^{14}\)C]-empagliflozin solution to healthy volunteers, approximately 96% of the drug-related radioactivity was eliminated in faeces (41%) or urine (54%). The majority of drug-related radioactivity recovered in faeces was unchanged parent drug and approximately half of drug-related radioactivity excreted in urine was unchanged parent drug.

**Special populations**

**Renal impairment**
In patients with mild, moderate or severe renal impairment (creatinine clearance <30 - <90 ml/min) and patients with kidney failure/end stage renal disease (ESRD), AUC of empagliflozin increased by
approximately 18%, 20%, 66%, and 48%, respectively compared to subjects with normal renal function. Peak plasma levels of empagliflozin were similar in subjects with moderate renal impairment and kidney failure/ESRD compared to patients with normal renal function. Peak plasma levels of empagliflozin were roughly 20% higher in subjects with mild and severe renal impairment as compared to subjects with normal renal function. The population pharmacokinetic analysis showed that the apparent oral clearance of empagliflozin decreased with a decrease in creatinine clearance leading to an increase in drug exposure.

**Hepatic impairment**
In subjects with mild, moderate, and severe hepatic impairment according to the Child-Pugh classification, AUC of empagliflozin increased approximately by 23%, 47%, and 75% and Cmax by approximately 4%, 23%, and 48%, respectively, compared to subjects with normal hepatic function.

**Body Mass Index**
Body mass index had no clinically relevant effect on the pharmacokinetics of empagliflozin based on the population pharmacokinetic analysis. In this analysis, AUC was estimated to be 5.82%, 10.4%, and 17.3% lower in subjects with BMI of 30, 35, and 45 kg/m², respectively, compared to subjects with a body mass index of 25 kg/m².

**Gender**
Gender had no clinically relevant effect on the pharmacokinetics of empagliflozin based on the population pharmacokinetic analysis.

**Race**
In the population pharmacokinetic analysis, AUC was estimated to be 13.5% higher in Asians with a body mass index of 25 kg/m² compared to non-Asians with a body mass index of 25 kg/m².

**Elderly**
Age did not have a clinically meaningful impact on the pharmacokinetics of empagliflozin based on the population pharmacokinetic analysis.

**Paediatric population**
Studies characterising the pharmacokinetics of empagliflozin in paediatric patients have not been performed.

**Metformin**

**Absorption**
After an oral dose of metformin, tmax is reached in 2.5 hours. Absolute bioavailability of a 500 mg or 850 mg metformin hydrochloride tablet is approximately 50-60% in healthy subjects. After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%. After oral administration, metformin absorption is saturable and incomplete. It is assumed that the pharmacokinetics of metformin absorption are non-linear. At the recommended metformin doses and dosing schedules, steady-state plasma concentrations are reached within 24 to 48 hours and are generally less than 1 microgram/ml. In controlled clinical trials, maximum metformin plasma levels (Cmax) did not exceed 5 microgram/ml, even at maximum doses.

Food decreases the extent and slightly delays the absorption of metformin. Following administration of a dose of 850 mg metformin hydrochloride, a 40% lower plasma peak concentration, a 25% decrease in AUC and a 35 minute prolongation of the time to peak plasma concentration were observed. The clinical relevance of these decreases is unknown.

**Distribution**
Plasma protein binding is negligible. Metformin partitions into erythrocytes. The blood peak is lower than the plasma peak and appears at approximately the same time. The red blood cells most likely represent a secondary compartment of distribution. The mean volume of distribution (Vd) ranged between 63 - 276 l.
**Biotransformation**
Metformin is excreted unchanged in the urine. No metabolites have been identified in humans.

**Elimination**
Renal clearance of metformin is >400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion. Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 hours.

When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and thus the elimination half-life is prolonged, leading to increased levels of metformin in plasma.

**Special populations**

**Paediatric population**
Single dose study: after single doses of metformin hydrochloride 500 mg, paediatric patients have shown a similar pharmacokinetic profile to that observed in healthy adults.

Multiple-dose study: After repeated doses of 500 mg twice daily for 7 days in paediatric patients the peak plasma concentration (C_{max}) and systemic exposure (AUC_{0-t}) were approximately 33% and 40% lower, respectively, compared to diabetic adults who received repeated doses of 500 mg twice daily for 14 days. As the dose is individually titrated based on glycaemic control, this is of limited clinical relevance.

5.3 Preclinical safety data

**Empagliflozin and metformin**

General toxicity studies in rats of up to 13 weeks were performed with the combination of empagliflozin and metformin and did not reveal any additional target organs when compared to empagliflozin or metformin alone. Some responses were increased by the combination treatment, such as effects on renal physiology, electrolyte balance and acid/base state. However, only hypochloremia was considered adverse at exposures of approximately 9- and 3-times the clinical AUC exposure of the maximum recommended dose of empagliflozin and metformin, respectively.

An embryofetal development study in pregnant rats did not indicate a teratogenic effect attributed to the co-administration of empagliflozin and metformin at exposures of approximately 14-times the clinical AUC exposure of empagliflozin associated with the highest dose, and 4-times the clinical AUC exposure of metformin associated with the 2000 mg dose.

**Empagliflozin**

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity, fertility and early embryonic development.

In long term toxicity studies in rodents and dogs, signs of toxicity were observed at exposures greater than or equal to 10-times the clinical dose of empagliflozin. Most toxicity was consistent with secondary pharmacology related to urinary glucose loss and electrolyte imbalances including decreased body weight and body fat, increased food consumption, diarrhoea, dehydration, decreased serum glucose and increases in other serum parameters reflective of increased protein metabolism and gluconeogenesis, urinary changes such as polyuria and glucosuria, and microscopic changes including mineralisation in kidney and some soft and vascular tissues. Microscopic evidence of the effects of exaggerated pharmacology on the kidney observed in some species included tubular dilatation, and tubular and pelvic mineralisation at approximately 4-times the clinical AUC exposure of empagliflozin associated with the 25 mg dose.

Empagliflozin is not genotoxic.
In a 2 year carcinogenicity study, empagliflozin did not increase the incidence of tumours in female rats up to the highest dose of 700 mg/kg/day, which corresponds to approximately 72-times the maximal clinical AUC exposure to empagliflozin. In male rats, treatment-related benign vascular proliferative lesions (haemangiomas) of the mesenteric lymph node were observed at the highest dose, but not at 300 mg/kg/day, which corresponds to approximately 26-times the maximal clinical exposure to empagliflozin. Interstitial cell tumours in the testes were observed with a higher incidence in rats at 300 mg/kg/day and above, but not at 100 mg/kg/day which corresponds to approximately 18-times the maximal clinical exposure to empagliflozin. Both tumours are common in rats and are unlikely to be relevant to humans.

Empagliflozin did not increase the incidence of tumours in female mice at doses up to 1,000 mg/kg/day, which corresponds to approximately 62-times the maximal clinical exposure to empagliflozin. Empagliflozin induced renal tumours in male mice at 1,000 mg/kg/day, but not at 300 mg/kg/day, which corresponds to approximately 11-times the maximal clinical exposure to empagliflozin. The mode of action for these tumours is dependent on the natural predisposition of the male mouse to renal pathology and a metabolic pathway not reflective of humans. The male mouse renal tumours are considered not relevant to humans.

At exposures sufficiently in excess of exposure in humans after therapeutic doses, empagliflozin had no adverse effects on fertility or early embryonic development. Empagliflozin administered during the period of organogenesis was not teratogenic. Only at maternally toxic doses, empagliflozin also caused bent limb bones in the rat and increased embryofetal loss in the rabbit.

In pre- and postnatal toxicity studies in rats, reduced weight gain of offspring was observed at maternal exposures approximately 4-times the maximal clinical exposure to empagliflozin. No such effect was seen at systemic exposure equal to the maximal clinical exposure to empagliflozin. The relevance of this finding to humans is unclear.

In a juvenile toxicity study in the rat, when empagliflozin was administered from postnatal day 21 until postnatal day 90, non-adverse, minimal to mild renal tubular and pelvic dilation in juvenile rats was seen only at 100 mg/kg/day, which approximates 11-times the maximum clinical dose of 25 mg. These findings were absent after a 13 weeks drug-free recovery period.

Metformin

Preclinical data for metformin reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, or carcinogenic potential or reproductive toxicity. At dose levels of 500 mg/kg/day administered to Wistar Hannover rats, associated with 7-times the maximum recommended human dose (MRHD) of metformin, teratogenicity of metformin was observed, mostly evident as an increase in the number of skeletal malformations.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Synjardy 5 mg/850 mg film-coated tablets and Synjardy 5 mg/1,000 mg film-coated tablets
Tablet core
Maize starch
Copovidone (K-value nominally 28)
Colloidal anhydrous silica
Magnesium stearate

Film-coating
Hypermellose
Macrogol 400
Titanium dioxide (E171)
Talc
Iron oxide yellow (E172)

Synjardy 12.5 mg/850 mg film-coated tablets and Synjardy 12.5 mg/1,000 mg film-coated tablets

Tablet core
Maize starch
Copovidone (K-value nominally 28)
Colloidal anhydrous silica
Magnesium stearate

Film-coating
Hypromellose
Macrogol 400
Titanium dioxide (E171)
Talc
Iron oxide black (E172)
Iron oxide red (E172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

PVC/PVDC/aluminium perforated unit dose blisters.
Pack sizes of 10 x 1, 14 x 1, 30 x 1, 56 x 1, 60 x 1, 90 x 1 and 100 x 1 film-coated tablets and multipacks containing 120 (2 packs of 60 x 1), 180 (2 packs of 90 x 1) and 200 (2 packs of 100 x 1) film-coated tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH
Binger Str. 173
D-55216 Ingelheim am Rhein
Germany
8. MARKETING AUTHORISATION NUMBER(S)

Synjardy 5 mg/850 mg film-coated tablets
EU/1/15/1003/001
EU/1/15/1003/002
EU/1/15/1003/003
EU/1/15/1003/004
EU/1/15/1003/005
EU/1/15/1003/037
EU/1/15/1003/006
EU/1/15/1003/007
EU/1/15/1003/008
EU/1/15/1003/009

Synjardy 5 mg/1,000 mg film-coated tablets
EU/1/15/1003/010
EU/1/15/1003/011
EU/1/15/1003/012
EU/1/15/1003/013
EU/1/15/1003/014
EU/1/15/1003/038
EU/1/15/1003/015
EU/1/15/1003/016
EU/1/15/1003/017
EU/1/15/1003/018

Synjardy 12.5 mg/850 mg film-coated tablets
EU/1/15/1003/019
EU/1/15/1003/020
EU/1/15/1003/021
EU/1/15/1003/022
EU/1/15/1003/023
EU/1/15/1003/039
EU/1/15/1003/024
EU/1/15/1003/025
EU/1/15/1003/026
EU/1/15/1003/027

Synjardy 12.5 mg/1,000 mg film-coated tablets
EU/1/15/1003/028
EU/1/15/1003/029
EU/1/15/1003/030
EU/1/15/1003/031
EU/1/15/1003/032
EU/1/15/1003/040
EU/1/15/1003/033
EU/1/15/1003/034
EU/1/15/1003/035
EU/1/15/1003/036

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 27 May 2015
10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
ANNEX II

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORIZATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Boehringer Ingelheim Pharma GmbH & Co.KG  
Binger Strasse 173  
55216 Ingelheim am Rhein  
Germany

Boehringer Ingelheim Ellas A.E.  
5th km Paiania – Markopoulo  
Koropi Attiki, 19400  
Greece

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
### 1. NAME OF THE MEDICINAL PRODUCT

Synjardy 5 mg/850 mg film-coated tablets  
empagliflozin/metformin hydrochloride

### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 5 mg empagliflozin and 850 mg metformin hydrochloride.

### 3. LIST OF EXCIPIENTS

### 4. PHARMACEUTICAL FORM AND CONTENTS

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>14 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>30 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>56 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>60 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>90 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>100 x 1</td>
<td>film-coated tablets</td>
</tr>
</tbody>
</table>

### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.  
Oral use

### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

### 8. EXPIRY DATE

EXP

### 9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH
55216 Ingelheim am Rhein
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1003/001 10 film-coated tablets
EU/1/15/1003/002 14 film-coated tablets
EU/1/15/1003/003 30 film-coated tablets
EU/1/15/1003/004 56 film-coated tablets
EU/1/15/1003/005 60 film-coated tablets
EU/1/15/1003/037 90 film-coated tablets
EU/1/15/1003/006 100 film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Synjardy 5 mg/850 mg
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

**BLISTERS (perforated)**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td><strong>NAME OF THE MEDICINAL PRODUCT</strong></td>
</tr>
<tr>
<td></td>
<td>Synjardy 5 mg/850 mg tablets empagliflozin/metformin HCL</td>
</tr>
<tr>
<td>2.</td>
<td><strong>NAME OF THE MARKETING AUTHORISATION HOLDER</strong></td>
</tr>
<tr>
<td></td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td>3.</td>
<td><strong>EXPIRY DATE</strong></td>
</tr>
<tr>
<td></td>
<td>EXP</td>
</tr>
<tr>
<td>4.</td>
<td><strong>BATCH NUMBER</strong></td>
</tr>
<tr>
<td></td>
<td>Lot</td>
</tr>
<tr>
<td>5.</td>
<td><strong>OTHER</strong></td>
</tr>
</tbody>
</table>
1. NAME OF THE MEDICINAL PRODUCT

Synjardy 5 mg/850 mg film-coated tablets
empagliflozin/metformin hydrochloride

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 5 mg empagliflozin and 850 mg metformin hydrochloride.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

60 x 1 film-coated tablets. Component of a multipack, cannot be sold separately.
90 x 1 film-coated tablets. Component of a multipack, cannot be sold separately.
100 x 1 film-coated tablets. Component of a multipack, cannot be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH
55216 Ingelheim am Rhein
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1003/007 120 (2 x 60 x 1) film-coated tablets
EU/1/15/1003/008 180 (2 x 90 x 1) film-coated tablets
EU/1/15/1003/009 200 (2 x 100 x 1) film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Synjardy 5 mg/850 mg
<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</th>
</tr>
</thead>
<tbody>
<tr>
<td>OUTER WRAPPER LABEL ON MULTIPACKS – INCLUDING THE BLUE BOX – 5 mg/850 mg</td>
</tr>
</tbody>
</table>

### 1. NAME OF THE MEDICINAL PRODUCT

Synjardy 5 mg/850 mg film-coated tablets
empagliflozin/metformin hydrochloride

### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 5 mg empagliflozin and 850 mg metformin hydrochloride.

### 3. LIST OF EXCIPIENTS

### 4. PHARMACEUTICAL FORM AND CONTENTS

Multipack comprising 2 packs, each containing 60 x 1 film-coated tablets.
Multipack comprising 2 packs, each containing 90 x 1 film-coated tablets.
Multipack comprising 2 packs, each containing 100 x 1 film-coated tablets.

### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

### 8. EXPIRY DATE

EXP

### 9. SPECIAL STORAGE CONDITIONS

### 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH
55216 Ingelheim am Rhein
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1003/007 120 (2 x 60 x 1) film-coated tablets
EU/1/15/1003/008180 (2 x 90 x 1) film-coated tablets
EU/1/15/1003/009 200 (2 x 100 x 1) film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Synjardy 5 mg/850 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

Synjardy 5 mg/1,000 mg film-coated tablets
empagliflozin/metformin hydrochloride

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 5 mg empagliflozin and 1,000 mg metformin hydrochloride.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>14 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>30 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>56 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>60 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>90 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>100 x 1</td>
<td>film-coated tablets</td>
</tr>
</tbody>
</table>

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH
55216 Ingelheim am Rhein
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1003/010 10 film-coated tablets
EU/1/15/1003/011 14 film-coated tablets
EU/1/15/1003/012 30 film-coated tablets
EU/1/15/1003/013 56 film-coated tablets
EU/1/15/1003/014 60 film-coated tablets
EU/1/15/1003/038 90 film-coated tablets
EU/1/15/1003/015 100 film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Synjardy 5 mg/1,000 mg
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

**BLISTERS (perforated)**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synjardy 5 mg/1,000 mg tablets</td>
</tr>
<tr>
<td>empagliflozin/metformin HCL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. NAME OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boehringer Ingelheim</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. OTHER</th>
</tr>
</thead>
</table>
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**MULTIPACKS – INTERMEDIATE CARTON WITHOUT BLUE BOX – 5 mg/1,000 mg**

### 1. NAME OF THE MEDICINAL PRODUCT

Synjardy 5 mg/1,000 mg film-coated tablets
empagliflozin/metformin hydrochloride

### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 5 mg empagliflozin and 1,000 mg metformin hydrochloride.

### 3. LIST OF EXCIPIENTS

### 4. PHARMACEUTICAL FORM AND CONTENTS

60 x 1 film-coated tablets. Component of a multipack, cannot be sold separately.
90 x 1 film-coated tablets. Component of a multipack, cannot be sold separately.
100 x 1 film-coated tablets. Component of a multipack, cannot be sold separately.

### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

### 8. EXPIRY DATE

EXP

### 9. SPECIAL STORAGE CONDITIONS

### 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH
55216 Ingelheim am Rhein
Germany

12. MARKETING AUTHORITY NUMBER(S)

EU/1/15/1003/016 120 (2 x 60 x 1) film-coated tablets
EU/1/15/1003/017 180 (2 x 90 x 1) film-coated tablets
EU/1/15/1003/018 200 (2 x 100 x 1) film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Synjardy 5 mg/1,000 mg
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

#### OUTER WRAPPER LABEL ON MULTIPACKS – INCLUDING THE BLUE BOX – 5 mg/1,000 mg

1. **NAME OF THE MEDICINAL PRODUCT**
   
   Synjardy 5 mg/1,000 mg film-coated tablets
   empagliflozin/metformin hydrochloride

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**
   
   Each tablet contains 5 mg empagliflozin and 1,000 mg metformin hydrochloride.

3. **LIST OF EXCIPIENTS**

4. **PHARMACEUTICAL FORM AND CONTENTS**
   
   Multipack comprising 2 packs, each containing 60 x 1 film-coated tablets.
   Multipack comprising 2 packs, each containing 90 x 1 film-coated tablets.
   Multipack comprising 2 packs, each containing 100 x 1 film-coated tablets.

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**
   
   Read the package leaflet before use.
   Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**
   
   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**
   
   EXP

9. **SPECIAL STORAGE CONDITIONS**

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH
55216 Ingelheim am Rhein
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1003/016 120 (2 x 60 x 1) film-coated tablets
EU/1/15/1003/017 180 (2 x 90 x 1) film-coated tablets
EU/1/15/1003/018 200 (2 x 100 x 1) film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Synjardy 5 mg/1,000 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

Synjardy 12.5 mg/850 mg film-coated tablets
empagliflozin/metformin hydrochloride

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 12.5 mg empagliflozin and 850 mg metformin hydrochloride.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

10 x 1 film-coated tablets
14 x 1 film-coated tablets
30 x 1 film-coated tablets
56 x 1 film-coated tablets
60 x 1 film-coated tablets
90 x 1 film-coated tablets
100 x 1 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
| 10. | SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE |
| 11. | NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER |
|     | Boehringer Ingelheim International GmbH |
|     | 55216 Ingelheim am Rhein |
|     | Germany |
| 12. | MARKETING AUTHORISATION NUMBER(S) |
|     | EU/1/15/1003/019 10 film-coated tablets |
|     | EU/1/15/1003/020 14 film-coated tablets |
|     | EU/1/15/1003/021 30 film-coated tablets |
|     | EU/1/15/1003/022 56 film-coated tablets |
|     | EU/1/15/1003/023 60 film-coated tablets |
|     | EU/1/15/1003/039 90 film-coated tablets |
|     | EU/1/15/1003/024 100 film-coated tablets |
| 13. | BATCH NUMBER |
|     | Lot |
| 14. | GENERAL CLASSIFICATION FOR SUPPLY |
|     | Medicinal product subject to medical prescription. |
| 15. | INSTRUCTIONS ON USE |
| 16. | INFORMATION IN BRAILLE |
|     | Synjardy 12.5 mg/850 mg |
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

**BLISTERS (perforated)**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synjardy 12.5 mg/850 mg tablets</td>
</tr>
<tr>
<td>empagliflozin/metformin HCL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. NAME OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boehringer Ingelheim</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. OTHER</th>
</tr>
</thead>
</table>
1. NAME OF THE MEDICINAL PRODUCT

Synjardy 12.5 mg/850 mg film-coated tablets
empagliflozin/metformin hydrochloride

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 12.5 mg empagliflozin and 850 mg metformin hydrochloride.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

60 x 1 film-coated tablets. Component of a multipack, cannot be sold separately.
90 x 1 film-coated tablets. Component of a multipack, cannot be sold separately.
100 x 1 film-coated tablets. Component of a multipack, cannot be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
### 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH  
55216 Ingelheim am Rhein  
Germany

### 12. MARKETING AUTHORISATION NUMBER(S)

- EU/1/15/1003/025 120 (2 x 60 x 1) film-coated tablets
- EU/1/15/1003/026 180 (2 x 90 x 1) film-coated tablets
- EU/1/15/1003/027 200 (2 x 100 x 1) film-coated tablets

### 13. BATCH NUMBER

Lot

### 14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

### 15. INSTRUCTIONS ON USE

### 16. INFORMATION IN BRAILLE

Synjardy 12.5 mg/850 mg
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**OUTER WRAPPER LABEL ON MULTIPACKS – INCLUDING THE BLUE BOX – 12.5 mg/850 mg**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synjardy 12.5 mg/850 mg film-coated tablets empagliflozin/metformin hydrochloride</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Each tablet contains 12.5 mg empagliflozin and 850 mg metformin hydrochloride.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. LIST OF EXCIPIENTS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>4. PHARMACEUTICAL FORM AND CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multipack comprising 2 packs, each containing 60 x 1 film-coated tablets.</td>
</tr>
<tr>
<td>Multipack comprising 2 packs, each containing 90 x 1 film-coated tablets.</td>
</tr>
<tr>
<td>Multipack comprising 2 packs, each containing 100 x 1 film-coated tablets.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
<tr>
<td>Oral use</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. OTHER SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9. SPECIAL STORAGE CONDITIONS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</th>
</tr>
</thead>
</table>
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH
55216 Ingelheim am Rhein
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1003/025 120 (2 x 60 x 1) film-coated tablets
EU/1/15/1003/026 180 (2 x 90 x 1) film-coated tablets
EU/1/15/1003/027 200 (2 x 100 x 1) film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Synjardy 12.5 mg/850 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

Synjardy 12.5 mg/1,000 mg film-coated tablets
empagliflozin/metformin hydrochloride

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 12.5 mg empagliflozin and 1,000 mg metformin hydrochloride.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

10 x 1 film-coated tablets
14 x 1 film-coated tablets
30 x 1 film-coated tablets
56 x 1 film-coated tablets
60 x 1 film-coated tablets
90 x 1 film-coated tablets
100 x 1 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORIZATION HOLDER

Boehringer Ingelheim International GmbH
55216 Ingelheim am Rhein
Germany

12. MARKETING AUTHORIZATION NUMBER(S)

EU/1/15/1003/028 10 film-coated tablets
EU/1/15/1003/029 14 film-coated tablets
EU/1/15/1003/030 30 film-coated tablets
EU/1/15/1003/031 56 film-coated tablets
EU/1/15/1003/032 60 film-coated tablets
EU/1/15/1003/040 90 film-coated tablets
EU/1/15/1003/033 100 film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Synjardy 12.5 mg/1,000 mg
<table>
<thead>
<tr>
<th><strong>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BLISTERS (perforated)</strong></td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT**

   Synjardy 12.5 mg/1,000 mg tablets
empagliflozin/metformin HCL

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**

   Boehringer Ingelheim

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **OTHER**
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**MULTIPACKS – INTERMEDIATE CARTON WITHOUT BLUE BOX – 12.5 mg/1,000 mg**

1. **NAME OF THE MEDICINAL PRODUCT**

   Synjardy 12.5 mg/1,000 mg film-coated tablets
   empagliflozin/metformin hydrochloride

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each tablet contains 12.5 mg empagliflozin and 1,000 mg metformin hydrochloride.

3. **LIST OF EXCIPIENTS**

4. **PHARMACEUTICAL FORM AND CONTENTS**

   - 60 x 1 film-coated tablets. Component of a multipack, cannot be sold separately.
   - 90 x 1 film-coated tablets. Component of a multipack, cannot be sold separately.
   - 100 x 1 film-coated tablets. Component of a multipack, cannot be sold separately.

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   Read the package leaflet before use.
   Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH
55216 Ingelheim am Rhein
Germany

12. MARKETING AUTHORITY NUMBER(S)

EU/1/15/1003/034 120 (2 x 60 x 1) film-coated tablets
EU/1/15/1003/035 180 (2 x 90 x 1) film-coated tablets
EU/1/15/1003/036 200 (2 x 100 x 1) film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Synjardy 12.5 mg/1,000 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER WRAPPER LABEL ON MULTIPACKS – INCLUDING THE BLUE BOX – 12.5 mg/1,000 mg

1. NAME OF THE MEDICINAL PRODUCT

Synjardy 12.5 mg/1,000 mg film-coated tablets
empagliflozin/metformin hydrochloride

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 12.5 mg empagliflozin and 1,000 mg metformin hydrochloride.

3. LIST OF EXCPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Multipack comprising 2 packs, each containing 60 x 1 film-coated tablets.
Multipack comprising 2 packs, each containing 90 x 1 film-coated tablets.
Multipack comprising 2 packs, each containing 100 x 1 film-coated tablets.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
<table>
<thead>
<tr>
<th>Section</th>
<th>Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</td>
<td>Boehringer Ingelheim International GmbH 55216 Ingelheim am Rhein Germany</td>
</tr>
<tr>
<td>12. MARKETING AUTHORISATION NUMBER(S)</td>
<td>EU/1/15/1003/034 120 (2 x 60 x 1) film-coated tablets  EU/1/15/1003/035 180 (2 x 90 x 1) film-coated tablets  EU/1/15/1003/036 200 (2 x 100 x 1) film-coated tablets</td>
</tr>
<tr>
<td>13. BATCH NUMBER</td>
<td>Lot</td>
</tr>
<tr>
<td>14. GENERAL CLASSIFICATION FOR SUPPLY</td>
<td>Medicinal product subject to medical prescription.</td>
</tr>
<tr>
<td>15. INSTRUCTIONS ON USE</td>
<td></td>
</tr>
<tr>
<td>16. INFORMATION IN BRAILLE</td>
<td>Synjardy 12.5 mg/1,000 mg</td>
</tr>
</tbody>
</table>
B. PACKAGE LEAFLET
Package leaflet: Information for the patient

Synjardy 5 mg/850 mg film-coated tablets
Synjardy 5 mg/1,000 mg film-coated tablets
Synjardy 12.5 mg/850 mg film-coated tablets
Synjardy 12.5 mg/1,000 mg film-coated tablets
Empagliflozin/metformin hydrochloride

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Synjardy is and what it is used for
2. What you need to know before you take Synjardy
3. How to take Synjardy
4. Possible side effects
5. How to store Synjardy
6. Contents of the pack and other information

1. What Synjardy is and what it is used for

Synjardy is a diabetes medicine that contains two active substances called empagliflozin and metformin.
- Empagliflozin works by blocking a protein in the kidneys called sodium glucose co-transporter 2 (SGLT2). SGLT2 prevents glucose (blood sugar) from being lost in urine by absorbing glucose back into the bloodstream as blood is being filtered in the kidneys. By blocking this protein, the medicine causes blood sugar to be removed via the urine. This helps to lower blood sugar levels, which are too high in patients with type 2 diabetes.
- Metformin works in a different way to lower blood sugar levels, mainly by blocking glucose production in the liver.

Synjardy is added to diet and exercise to treat type 2 diabetes in adult patients (aged 18 years and older) whose diabetes cannot be controlled by adding metformin alone or metformin with other medicines for diabetes.

Synjardy can also be combined with other medicines. These may be medicines taken by mouth or insulin given by injection.

In addition, Synjardy can be used as an alternative to taking both empagliflozin and metformin as single tablets. To avoid overdose, do not continue taking empagliflozin and metformin tablets separately, if you are taking this medicine.

It is important that you continue with your diet and exercise plan as told by your doctor, pharmacist or nurse.
What is type 2 diabetes?
Type 2 diabetes is a disease that comes from both your genes and your lifestyle. If you have type 2 diabetes, your pancreas does not make enough insulin to control the level of glucose in your blood, and your body is unable to use its own insulin effectively. This results in high levels of glucose in your blood which can lead to medical problems like heart disease, kidney disease, blindness, and poor circulation in your limbs.

2. What you need to know before you take Synjardy

Do not take Synjardy:
- if you are allergic to empagliflozin, metformin or any of the other ingredients of this medicine (listed in section 6);
- if you have uncontrolled diabetes, with e.g. severe hyperglycaemia (high blood glucose), nausea, vomiting, dehydration, rapid weight loss or ketoacidosis. Ketoacidosis is a condition in which substances called ‘ketone bodies’ accumulate in the blood and which can lead to diabetic pre-coma. Symptoms include rapid weight loss, feeling sick or being sick, stomach pain, fast and deep breathing, sleepiness or unusual fruity odour of the breath;
- if you have had a diabetic pre-coma;
- if you have problems with your kidneys;
- if you have a severe infection such as an infection affecting your lung or bronchial system or your kidney. Severe infections may lead to kidney problems, which can put you at risk for lactic acidosis (see 'Warnings and precautions');
- if you have lost a lot of water from your body (dehydration), e.g. due to long-lasting or severe diarrhoea, or if you have vomited several times in a row. Dehydration may lead to kidney problems, which can put you at risk for lactic acidosis (see 'Warnings and precautions');
- if you are treated for acute heart failure or have recently had a heart attack, have severe problems with your circulation (such as shock) or have breathing difficulties. This may lead to a lack in oxygen supply to tissue which can put you at risk for lactic acidosis (see section ‘Warnings and precautions’);
- if you have problems with your liver;
- if you drink alcohol to excess, either every day or only from time to time (see section “Synjardy with alcohol”).

Warnings and precautions
Talk to your doctor, pharmacist or nurse before taking this medicine, and during treatment:
- if you have “type 1 diabetes” – this type usually starts when you are young and your body does not produce any insulin;
- if you experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth, or a different odour to your urine or sweat, contact a doctor or the nearest hospital straight away. These symptoms could be a sign of “diabetic ketoacidosis” – a problem you can get with diabetes because of increased levels of “ketone bodies” in your urine or blood, seen in tests. The risk of developing diabetic ketoacidosis may be increased with prolonged fasting, excessive alcohol consumption, dehydration, sudden reductions in insulin dose, or a higher need of insulin due to major surgery or serious illness.
- if you are 75 years old or older, as increased passing of urine due to the medicine may affect fluid balance in your body and increase your risk of dehydration. Possible signs are listed in section 4, ‘Possible side effects’, dehydration;
- if you are 85 years old or older as you should not start taking Synjardy;
- if you are being sick, have diarrhoea or fever, or if you are not able to eat or drink. These conditions can cause dehydration. Your doctor may ask you to stop taking Synjardy until you recover to prevent loss of too much body fluid;
- if you have a serious infection of the kidney or the urinary tract with fever. Your doctor may ask you to stop taking Synjardy until you have recovered;
• if you need to have an injection of contrast agent that contains iodine, for example before an X-ray or scan. You will need to tell your doctor and stop taking this medicine before, or at the time of the X-ray and for 2 or more days after depending on how your kidneys are working. Treatment with iodinated contrast agent can reduce your kidney function and increase the risk of side effects due to the metformin component. Make sure to ask your doctor for advice regarding when you can start your treatment again;
• if you are going to have an operation under anaesthesia. You should stop taking Synjardy at least 48 hours before planned surgery with general, spinal or peridural anaesthesia and should not start again until at least 48 hours afterwards. Due to the metformin component, co-administration of anaesthesia can increase the risk of side effects. Follow your doctor’s instructions about stopping and re-starting your medicine.

**Please note the following particular risk of lactic acidosis.**
Due to the metformin component, Synjardy may cause a very rare, but very serious complication called lactic acidosis, particularly if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, prolonged fasting or alcohol intake, body fluid deficit (dehydration) due to severe diarrhoea or vomiting, liver problems and any medical conditions in which a region of the body is deprived with a lack of oxygen supply (such as acute severe heart diseases).

It is important to you to comply with your medication intake, dietary instructions and regular exercise program because this can reduce the risk of lactic acidosis.

The onset of lactic acidosis can be subtle and the symptoms can be non-specific such as vomiting, bellyache (abdominal pain) with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in breathing. Further symptoms are reduced body temperature and heart beat.

**If you experience some of these symptoms, you should seek immediately medical attention, as lactic acidosis may lead to coma. Stop taking Synjardy immediately and contact a doctor or the nearest hospital straight away.**

**Kidney function**
Your kidneys will be tested by a blood test before you start taking and while you are taking this medicine.

**Urine glucose**
Because of how this medicine works, your urine will test positive for sugar while you are taking this medicine.

**Children and adolescents**
This medicine is not recommended for use in children and adolescents under 18 years, because it has not been studied in these patients.

**Other medicines and Synjardy**
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

It is important to tell your doctor if you are taking:
• a medicine used to remove water from the body (diuretic), as Synjardy may increase the risk of losing too much fluid. Your doctor may ask you to stop taking Synjardy. Possible signs of losing too much fluid from your body are listed in section 4 ‘Possible side effects’.
• other medicines that lower the amount of sugar in your blood such as insulin or a “sulphonylurea” medicine. Your doctor may want to lower the dose of these other medicines, to prevent your blood sugar levels from getting too low (hypoglycaemia).
• cimetidine, a medicine used to treat stomach problems.
• bronchodilators (beta-2 agonists) which are used to treat asthma.
• corticosteroids (given by mouth, as an injection, or inhaled), which are used to treat inflammation in diseases like asthma and arthritis.
• medicines that contain alcohol (see section ‘Synjardy with alcohol’).
• iodinated contrast agents (medicines used during an X-ray, see section 2 ‘Warnings and precautions’).
Synjardy with alcohol
There is an increased risk of lactic acidosis following excessive alcohol consumption (particularly in the case of fasting, malnutrition, or liver disease). Therefore, avoid consumption of alcohol and medicines containing alcohol when taking Synjardy (see section 4, ‘Possible side effects’).

Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Do not take Synjardy if you are pregnant. It is unknown if this medicine is harmful to the unborn child.

Metformin passes into human milk in small amounts. It is not known whether empagliflozin passes into human breast milk. Do not take Synjardy if you are breast-feeding.

Driving and using machines
Synjardy has minor influence on the ability to drive and use machines.

Taking this medicine in combination with medicines called sulphonylureas or with insulin can cause blood sugar levels to drop too low (hypoglycaemia), which may cause symptoms such as shaking, sweating and change in vision, and may affect your ability to drive and use machines. Do not drive or use any tools or machines if you feel dizzy while taking Synjardy.

3. How to take Synjardy

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

How much to take
The dose of Synjardy varies depending on your condition and the doses of diabetes medicines you currently take. Your doctor will adjust your dose as necessary and tell you exactly which strength of the medicine to take.

The recommended dose is one tablet twice a day. Your doctor will normally start Synjardy treatment by prescribing the strength of tablet that supplies the same dose of metformin you are already taking (850 mg or 1,000 mg twice a day), and the lowest dose of empagliflozin (5 mg twice a day). If you are already taking both medicines separately, your doctor will start treatment with tablets of Synjardy that will supply the same amount of both.

Taking this medicine
- Swallow the tablet whole with water.
- Take the tablets with meals to lower your chance of an upset stomach.
- Take the tablet twice daily by mouth.

Your doctor may prescribe Synjardy together with another diabetes medicine. Remember to take all medicines as directed by your doctor to achieve the best results for your health. Your doctor may need to adjust your doses to control your blood sugar.

Diet and exercise can help your body use its blood sugar better. It is important to stay on the diet and exercise program recommended by your doctor while taking Synjardy.

If you take more Synjardy than you should
If you take more Synjardy tablets than you should have, you may experience lactic acidosis. Symptoms of lactic acidosis are non-specific such as feeling or being very sick, vomiting, stomach ache with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in
breathing. Further symptoms are reduced body temperature and heart beat. **If this happens to you, you may need immediate hospital treatment, as lactic acidosis can lead to coma.** Stop taking this medicine immediately and contact a doctor or the nearest hospital straight away (see section 4). Take the medicine pack with you.

**If you forget to take Synjardy**
If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose and go back to your regular schedule. Do not take a double dose of this medicine.

**If you stop taking Synjardy**
Do not stop taking Synjardy without first consulting your doctor. Your blood sugar levels may increase when you stop taking Synjardy.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

---

### 4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Stop taking Synjardy and see a doctor as soon as possible if you notice any of the following serious or potentially serious side effects:**

**Lactic acidosis.** Metformin, one of the active substances in this medicine, can cause a very rare (may affect up to 1 in 10,000 people) but serious side effect called ‘lactic acidosis’. This is a build-up of lactic acid in the blood that can cause death. Lactic acidosis is a medical emergency and must be treated in hospital. It particularly affects patients whose kidneys are not working properly.

Signs of ‘lactic acidosis’ are:
- feeling or being very sick
- vomiting, stomach ache
- muscular cramps
- severe tiredness
- difficulty breathing

If this happens to you, you may need immediate hospital treatment, as lactic acidosis may lead to coma. Stop taking this medicine immediately and contact a doctor or the nearest hospital straight away. Take the medicine pack with you.

**Contact a doctor or the nearest hospital straight away if you have any of the following side effects:**

**Diabetic ketoacidosis, seen rarely (may affect up to 1 in 1,000 people)**
These are the signs of diabetic ketoacidosis (see also section 2, ‘Warnings and precautions’):
- increased levels of “ketone bodies” in your urine or blood
- rapid weight loss
- feeling sick or being sick
- stomach pain
- excessive thirst
- fast and deep breathing
- confusion
- unusual sleepiness or tiredness
- a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat.
This may occur regardless of blood glucose level. Your doctor may decide to temporarily or permanently stop your treatment with Synjardy.

Contact your doctor as soon as possible if you notice the following side effects:

**Low blood sugar (hypoglycaemia), seen very commonly (may affect more than 1 in 10 people)**
If you take Synjardy with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is increased. The signs of low blood sugar may include:
- shaking, sweating, feeling very anxious or confused, fast heart beat
- excessive hunger, headache

Your doctor will tell you how to treat low blood sugar levels and what to do if you get any of the signs above. If you have symptoms of low blood sugar, eat glucose tablets, a high sugar snack or drink fruit juice. Measure your blood sugar if possible and rest.

**Urinary tract infection, seen commonly (may affect up to 1 in 10 people)**
The signs of urinary tract infection are:
- burning sensation when passing urine
- urine that appears cloudy
- pain in the pelvis, or mid-back pain (when kidneys are infected)

An urge to pass urine or more frequent urination may be due to the way Synjardy works, but as they can also be signs of urinary tract infection. If you note an increase in such symptoms, you should also contact your doctor.

**Dehydration, seen uncommonly (may affect up to 1 in 100 people)**
The signs of dehydration are not specific, but may include:
- unusual thirst
- lightheadedness or dizziness upon standing
- fainting or loss of consciousness

**Other side effects while taking Synjardy:**

Very common
- feeling sick (nausea), vomiting
- diarrhoea or stomach ache
- loss of appetite

Common
- genital yeast infection (thrush)
- passing more urine than usual or needing to pass urine more often
- itching
- changes the way things taste

Uncommon
- straining or pain when emptying the bladder

Very rare
- decreased vitamin B12 levels in the blood
- abnormalities in liver function tests, inflammation of the liver (hepatitis)
- redness of the skin (erythema) or an itchy rash (hives)
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Synjardy

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister and the carton after ‘EXP’. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not use this medicine if you notice that the packaging is damaged or shows signs of tampering.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Synjardy contains
The active substances are empagliflozin and metformin.
Each Synjardy 5 mg/850 mg film-coated tablet (tablet) contains 5 mg empagliflozin and 850 mg metformin hydrochloride.
Each Synjardy 5 mg/1,000 mg film-coated tablet (tablet) contains 5 mg empagliflozin and 1,000 mg metformin hydrochloride.
Each Synjardy 12.5 mg/850 mg film-coated tablet (tablet) contains 12.5 mg empagliflozin and 850 mg metformin hydrochloride.
Each Synjardy 12.5 mg/1,000 mg film-coated tablet (tablet) contains 12.5 mg empagliflozin and 1,000 mg metformin hydrochloride.

The other ingredient(s) are:

– Tablet core: maize starch, copovidone, colloidal anhydrous silica, magnesium stearate.
– Film coating: hypromellose, macrogol 400, titanium dioxide (E171), talc. Synjardy 5 mg/850 mg and Synjardy 5 mg/1,000 mg tablets also contain iron oxide yellow (E172). Synjardy 12.5 mg/850 mg and Synjardy 12.5 mg/1,000 mg tablets also contain iron oxide black (E172) and iron oxide red (E172).

What Synjardy looks like and contents of the pack
Synjardy 5 mg/850 mg film-coated tablets are yellowish white, oval, biconvex. They have “S5” and the Boehringer Ingelheim logo on one side and “850” on the other. The tablet is 19.2 mm long and has a width of 9.4 mm.
Synjardy 5 mg/1,000 mg film-coated tablets are brownish yellow, oval, biconvex. They have “S5” and the Boehringer Ingelheim logo on one side and “1000” on the other. The tablet is 21.1 mm long and has a width of 9.7 mm.
Synjardy 12.5 mg/850 mg film-coated tablets are pinkish white, oval, biconvex. They have “S12” and the Boehringer Ingelheim logo on one side and “850” on the other. The tablet is 19.2 mm long and has a width of 9.4 mm.
Synjardy 12.5 mg/1,000 mg film-coated tablets are dark brownish purple, oval, biconvex. They have “S12” and the Boehringer Ingelheim logo on one side and “1000” on the other. The tablet is 21.1 mm long and has a width of 9.7 mm.
The tablets are available in PVC/PVDC/aluminium perforated unit dose blisters. The pack sizes are 10 x 1, 14 x 1, 30 x 1, 56 x 1, 60 x 1, 90 x 1 and 100 x 1 film-coated tablets and multipacks containing 120 (2 packs of 60 x 1), 180 (2 packs of 90 x 1) and 200 (2 packs of 100 x 1) film-coated tablets.

Not all pack sizes may be marketed in your country.

**Marketing Authorisation Holder**

Boehringer Ingelheim International GmbH  
Binger Strasse 173  
55216 Ingelheim am Rhein  
Germany

**Manufacturer**  
Boehringer Ingelheim Pharma GmbH & Co. KG  
Binger Strasse 173  
55216 Ingelheim am Rhein  
Germany

Boehringer Ingelheim Ellas A.E.  
5th km Paiania – Markopoulo  
Koropi Attiki, 19400  
Greece
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

<table>
<thead>
<tr>
<th>Country</th>
<th>Company 1</th>
<th>Tel/Contact Information 1</th>
<th>Company 2</th>
<th>Tel/Contact Information 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>België/Belgique/Belgien</td>
<td>SCS Boehringer Ingelheim Comm.V</td>
<td>+32 2 773 33 11</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+370 37 473 922</td>
</tr>
<tr>
<td></td>
<td>Tel: +359 2 958 79 98</td>
<td></td>
<td>Lietuva</td>
<td></td>
</tr>
<tr>
<td>Lietuva</td>
<td>SCS Boehringer Ingelheim Comm.V</td>
<td>+32 2 773 33 11</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+370 37 473 922</td>
</tr>
<tr>
<td></td>
<td>Tel: +359 2 958 79 98</td>
<td></td>
<td>Lietuva</td>
<td></td>
</tr>
<tr>
<td>България</td>
<td>Бьорингер Ингелхайм РЦВ ГмбХ и Ко КГ -</td>
<td>+359 2 958 79 98</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+370 37 473 922</td>
</tr>
<tr>
<td></td>
<td>клон България</td>
<td></td>
<td>Lietuva</td>
<td></td>
</tr>
<tr>
<td>Česká republika</td>
<td>Boehringer Ingelheim spol. s r.o.</td>
<td>+420 234 655 111</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+370 37 473 922</td>
</tr>
<tr>
<td></td>
<td>Tel: +420 234 655 111</td>
<td></td>
<td>Lietuva</td>
<td></td>
</tr>
<tr>
<td>Danmark</td>
<td>Boehringer Ingelheim Danmark A/S</td>
<td>+45 39 15 88 88</td>
<td>Boehringer Ingelheim Ltd.</td>
<td>+44 1344 424 600</td>
</tr>
<tr>
<td></td>
<td>Tlf: +45 39 15 88 88</td>
<td></td>
<td>Boehringer Ingelheim Ltd.</td>
<td>+44 1344 424 600</td>
</tr>
<tr>
<td>Deutschland</td>
<td>Boehringer Ingelheim Pharma GmbH &amp; Co.KG</td>
<td>+49 (0) 800 77 90 900</td>
<td>Boehringer Ingelheim b.v.</td>
<td>+31 (0) 800 22 55 889</td>
</tr>
<tr>
<td></td>
<td>Tel: +49 (0) 800 77 90 900</td>
<td></td>
<td>Boehringer Ingelheim b.v.</td>
<td>+31 (0) 800 22 55 889</td>
</tr>
<tr>
<td></td>
<td>Lilly Deutschland GmbH</td>
<td>+49 (0) 6172 273 2222</td>
<td>Boehringer Ingelheim Norway KS</td>
<td>+47 66 76 13 00</td>
</tr>
<tr>
<td></td>
<td>Tel: +49 (0) 6172 273 2222</td>
<td></td>
<td>Boehringer Ingelheim Norway KS</td>
<td>+47 66 76 13 00</td>
</tr>
<tr>
<td>Eesti</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+372 612 8000</td>
<td>Boehringer Ingelheim Ellas A.E.</td>
<td>+30 2 10 89 06 300</td>
</tr>
<tr>
<td></td>
<td>Eesti filiaal</td>
<td></td>
<td>Boehringer Ingelheim Ellas A.E.</td>
<td>+30 2 10 89 06 300</td>
</tr>
<tr>
<td></td>
<td>Tel: +372 612 8000</td>
<td></td>
<td>Boehringer Ingelheim Ellas A.E.</td>
<td>+30 2 10 89 06 300</td>
</tr>
<tr>
<td>Elláda</td>
<td>Boehringer Ingelheim Ellas A.E.</td>
<td>+30 2 10 89 06 300</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+43 1 80 105-0</td>
</tr>
<tr>
<td></td>
<td>Tel: +30 2 10 89 06 300</td>
<td></td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+43 1 80 105-0</td>
</tr>
<tr>
<td>España</td>
<td>Boehringer Ingelheim España, S.A.</td>
<td>+34 93 404 51 00</td>
<td>Boehringer Ingelheim Sp.zo.o.</td>
<td>+48 22 699 0 699</td>
</tr>
<tr>
<td></td>
<td>Tel: +34 93 404 51 00</td>
<td></td>
<td>Boehringer Ingelheim Sp.zo.o.</td>
<td>+48 22 699 0 699</td>
</tr>
<tr>
<td></td>
<td>Lilly S.A.</td>
<td>+34 91 663 50 00</td>
<td>Boehringer Ingelheim, Unipessoal, Lda.</td>
<td>+351 21 313 53 00</td>
</tr>
<tr>
<td></td>
<td>Tel: +34 91 663 50 00</td>
<td></td>
<td>Boehringer Ingelheim, Unipessoal, Lda.</td>
<td>+351 21 313 53 00</td>
</tr>
<tr>
<td></td>
<td>Lilly France SAS</td>
<td>+33 1 55 49 34 34</td>
<td>Lilly Portugal Produtos Farmacêuticos, Lda</td>
<td>+351 21 412 66 00</td>
</tr>
<tr>
<td></td>
<td>Tel: +33 1 55 49 34 34</td>
<td></td>
<td>Lilly Portugal Produtos Farmacêuticos, Lda</td>
<td>+351 21 412 66 00</td>
</tr>
<tr>
<td>Hrvatska</td>
<td>Boehringer Ingelheim Zagreb d.o.o.</td>
<td>+385 1 2444 600</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+40 21 302 28 00</td>
</tr>
<tr>
<td></td>
<td>Tel: +385 1 2444 600</td>
<td></td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+40 21 302 28 00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Viena - Sucursala Bucureşti</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tel: +40 21 302 28 00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This leaflet was last revised in {MM/YYYY}.